Podcasts about Johns Hopkins

Calling out "Happy Christmas to all and to all a good-night,  Dr. Griffin and Vincent Racaniello discuss high path influenza in dairy herds in Wisconsin and Marburg virus in Ethiopia before Dr. Griffin then deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, the slightly higher association of COVID-19 infection with death than following influenza infection, benefit of passive infant immunization with niresevimab, association of COVID-19 vaccine immunogenicity protection against severe disease in vulnerable populations, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, effect of remdesivir and nirmatrelvir/ritonavir on COVID-19 associated mortality, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode USDA Confirms Highly Pathogenic Avian Influenza in a Dairy Herd in Wisconsin (USDA Animal and Plant Health Inspection Service) Update: Genetic Sequencing Results for Wisconsin Dairy Herd Detection of Highly Pathogenic Avian Influenza(USDA Animal and Plant Health Inspection Service) Marburg Outbreak in Ethiopia: Current Situation (CDC: Marburg Virus Disease) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles(CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) In call with clinicians, CDC recommends flu vaccines widely(CIDRAP) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) Increased 30-day Mortality Risk in Coronavirus Disease 2019 Compared to Seasonal Influenza (International Journal of Infectious Diseases) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns (JAMA) RSV Immunization Frequently Asked Questions(American Academy of Pediatrics) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Association between COVID-19 vaccine immunogenicity and protection against infection and severe disease in clinically vulnerable patient populations: a systematic review and meta-analysis of observational studies (Clinical Microbiology and Infection) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: an emulated target trial (Clinical Microbiology and Infection) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Long-COVID research just got a big funding boost: will it find new treatments? (Nature) Reaching out to US house representative Letters read on TWiV 1282 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

It's YOUR time to #EdUp with Dr. Anthony K. Wutoh, Provost, Howard UniversityIn this episode, sponsored by the ⁠⁠⁠ELIVE 2026 Conference in Denver, Colorado, April 19-22, & the 2026 InsightsEDU Conference in Fort Lauderdale, Florida, February 17-19,YOUR cohost is Megan Dusenbery, Chief Executive Officer, KnackYOUR host is ⁠Elvin Freytes⁠How does a provost increase graduation rates by over 20% & create programs like Karsh STEM Scholars & Humanities & Social Science Scholars that send students to PhD programs at Harvard, Stanford & Johns Hopkins?What happens when an HBCU partners with Google & Amazon Studios to create Tech Exchange & Howard Entertainment programs that give students real world experience in technology & the business of entertainment?How does a university leader with 30 years of experience think about AI's transformational impact on higher education while maintaining focus on ethics, access & preparing students for the world that's coming?Listen in to #EdUpThank YOU so much for tuning in. Join us on the next episode for YOUR time to EdUp!Connect with YOUR EdUp Team - ⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Elvin Freytes⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Dr. Joe Sallustio⁠⁠⁠⁠⁠● Join YOUR EdUp community at ⁠The EdUp Experience⁠We make education YOUR business!P.S. Want to get early, ad-free access & exclusive leadership content to help support the show? Then ⁠⁠​subscribe today​⁠⁠ to lock in YOUR $5.99/m lifetime supporters rate! This offer ends December 31, 2025!

Today, Dave Furfaro, Luke Hedrick, and Robert Wharton discuss the PREDMETH trial published in The New England Journal of Medicine in 2025. This was a non-inferiority trial comparing prednisone to methotrexate for upfront therapy in treatment-naive sarcoidosis patients. Listen in for a break down of the trial, analysis, and clinically applicable pearls. Article and Reference Todays’ episode discusses the PREDMETH trial published in NEJM in 2025. Kahlmann V, Janssen Bonás M, Moor CC, Grutters JC, Mostard RLM, van Rijswijk HNAJ, van der Maten J, Marges ER, Moonen LAA, Overbeek MJ, Koopman B, Loth DW, Nossent EJ, Wagenaar M, Kramer H, Wielders PLML, Bonta PI, Walen S, Bogaarts BAHA, Kerstens R, Overgaauw M, Veltkamp M, Wijsenbeek MS; PREDMETH Collaborators. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. N Engl J Med. 2025 Jul 17;393(3):231-242. doi: 10.1056/NEJMoa2501443. Epub 2025 May 18. PMID: 40387020. https://www.nejm.org/doi/full/10.1056/NEJMoa2501443 Meet Our Hosts Luke Hedrick is an Associate Editor at Pulm PEEPs and runs the Rapid Fire Journal Club Series. He is a senior PCCM fellow at Emory, and will be starting as a pulmonary attending at Duke University next year. Robert Wharton is a recurring guest on Pulm PEEPs as a part of our Rapid Fire Journal Club Series. He completed his internal medicine residency at Mt. Sinai in New York City, and is currently a first year pulmonary and critical care fellow at Johns Hopkins. Key Learning Points Clinical context Prednisone remains the traditional first-line treatment for pulmonary sarcoidosis when treatment is indicated, with evidence for short-term improvements in symptoms, radiographic findings, and pulmonary function—but with substantial, familiar steroid toxicities (weight gain, insomnia, HTN/DM, infection risk, etc.). Despite widespread use, glucocorticoids haven't been robustly tested head-to-head against many alternatives as initial therapy, and evidence for preventing long-term decline (especially in severe disease) is limited. Immunosuppressants (like methotrexate) are often used as steroid-sparing agents, but guideline recommendations are generally conditional/low-quality evidence, and practice varies. Why PREDMETH matters It addresses a real-world question: Can methotrexate be an initial alternative to prednisone in pulmonary sarcoidosis, rather than being reserved only for steroid-sparing later? It also probes a common clinical belief: MTX has slower onset than prednisone (often assumed, not well-proven). Trial design (what to know) Open-label, randomized, noninferiority trial across 17 hospitals in the Netherlands. Included patients with pulmonary sarcoidosis who had a clear pulmonary indication to start systemic therapy (moderate/severe symptoms plus objective risk features like reduced FVC/DLCO or documented decline, plus parenchymal abnormalities). Excluded: non–treatment-naïve patients and those whose primary indication was extrapulmonary disease. Treat-to-tolerability with escalation: both drugs started low and were slowly increased; switch/add-on allowed for inadequate efficacy or unacceptable side effects. Primary endpoint: change in FVC (with the usual caveat that FVC is “objective-ish,” but effort-dependent and not always patient-centered). Noninferiority margin: 5% FVC, justified as within biologic/measurement variation and “not clinically relevant.” Outcomes assessed at weeks 4, 16, 24; powered for ~110 patients to detect the NI margin. Patient population (who this applies to) Mostly middle-aged (~40s) with mild-to-moderate physiologic impairment on average (FVC ~77% predicted; DLCO ~70% predicted). Netherlands-based cohort with limited Black representation (~7%), which matters for generalizability. Would have been helpful to know more about comorbidities (e.g., diabetes), which can strongly influence prednisone risk. Main findings (what happened) Methotrexate was noninferior to prednisone at week 24 for FVC: Between-group difference in least-squares mean change at week 24: −1.17 percentage points (favoring prednisone) with CI −4.27 to +1.93, staying within the 5% NI margin. Timing mattered: Prednisone showed earlier benefit (notably by week 4) in FVC and across quality-of-life measures. By week 24, those early differences largely washed out—possibly because MTX “catches up,” and/or because crossover increased over time. In their reporting, MTX didn't meet noninferiority for FVC until week 24, supporting the practical message that prednisone works faster. Crossover and analysis nuance (important for interpretation) Crossover was fairly high, which complicates noninferiority interpretation: MTX arm: some switched to prednisone for adverse events and others had prednisone added for disease progression/persistent symptoms. Prednisone arm: some had MTX added. In noninferiority trials, heavy crossover can bias intention-to-treat analyses toward finding “no difference” (making noninferiority easier to claim). Per-protocol analyses avoid some of that but introduce other biases. They reported both. Safety signals (what to remember clinically) Adverse events were very common in both arms (almost everyone), mostly mild. Side-effect patterns fit expectations: Prednisone: more insomnia (and classic steroid issues). MTX: more headache/cough/rash, and notably liver enzyme elevations (about 1 in 4), with a small number discontinuing. Serious adverse events were rare; numbers were too small to confidently separate “signal vs noise,” but overall known risk profiles apply. Limitations (why you shouldn't over-read it) Open-label design, and FVC—while objective-ish—is still effort-dependent and can be influenced by expectation/behavior. Small trial, limiting subgroup conclusions (e.g., severity strata, different phenotypes). Generalizability issues (Netherlands demographics; US populations have higher rates of obesity/metabolic syndrome, which may tilt the steroid risk-benefit equation). Crossover reduces precision and interpretability of between-group differences over time. Practice implications (the “so what”) For many patients with pulmonary sarcoidosis needing systemic therapy, MTX is a reasonable initial alternative to prednisone when thinking long-term tolerability and steroid avoidance. Prednisone likely provides faster symptom/QoL relief in the first weeks—so it may be preferable when rapid improvement is important. The trial strengthens the case for a patient-centered discussion: short-term relief vs side-effect tradeoffs, and the possibility of early combination therapy in more severe cases (suggested, not proven).

Join us as we explore a critical question: What if the solution to America's number one killer isn't in the pharmacy, but in the kitchen? Today's guest is Dr. Elizabeth Klodas, a Mayo Clinic and Johns Hopkins-trained cardiologist who founded Step One Foods after realizing that doctors, including herself, weren't addressing the most powerful intervention for heart disease diet.Elizabeth Klodas, MD, Founder & Chief Medical Officer, Step One FoodsMegan Antonelli, Chief Executive Officer, HealthIMPACT Live

While we celebrate the remarkable achievement of 250 years of the US military being a bulwark of democracy, it is important to understand the intentionally laid foundations on which America's civil military relations tradition rests. Military deference to civilian authority and the legislature is a principle pioneered and championed by General George Washington, setting a powerful precedent for commanding officers to follow… with some instructive exceptions. As we look toward the New Year, and wearily at the political posturing of some military leaders, Kori Schake reminds us of a central theme from her new book, The State and the Soldier (Polity, 2025): “We want a military that's not partisan. We want a military that is subordinate to whatever lunatics the American public see fit to put into high office.” How are military leaders inherently political? How do we avoid forcing them to make partisan choices? And, as we have discussed all year, why does Congress refuse to exercise the powers it has, even in this realm?Kori Schake is a senior fellow and the Director of Foreign and Defense Policy studies at the American Enterprise Institute. Before joining AEI, Dr. Schake was the deputy director-general of the International Institute for Strategic Studies in London. She has had a distinguished career in government, working at the US State Department, the US Department of Defense, and the National Security Council at the White House. She was also senior policy advisor on the 2008 McCain campaign. She has taught at Stanford, West Point, Johns Hopkins, and the University of Maryland. Dr. Schake is the author of 5 books, with her newest titled “The State and the Soldier: A History of Civil-Military Relations in the United States.”Read the transcript here.Subscribe to our Substack here.Find The State and the Soldier here.

One of the two semifinals was a classic, fit for kids from 1 to 92 ... if you can handle stress, that is.  And we aren't just spouting cliches when we say this is as good as it gets -- in the history of the national semifinals since automatic bids were added and the playoffs expanded beyond four rounds in 1999, there have been only two years where both semifinals were close. It's far more likely that both of them are two-score games! So to get not just one good one, but one epic one, well, that's great. When Kaleb Blaha threaded the tiniest hole to find Blake Rohrer, and Rohrer ran untouched to the end zone for a 79-yard touchdown against Johns Hopkins, it not only sent the Falcons to the Stagg Bowl for the first time ever, it united a community, and was another memorable moment in a friendship between the two. They talk about it, how they met, how Blaha recruited Rohrer to come out for the UW-River Falls football team, and how the River Falls community reacted on Saturday night, in Around the Nation. 2016 Around the Nation column: Out of darkness, light, by Adam Turer, featuring the rebuilding UW-River Falls program At North Central, the Cardinals got the best passing performance of the season from Garet Wilson, and Jack Rummell had some amazing catches and runs. What did Wilson say to him before a third-and-8 play, and how did Rummell respond? We also hear from transfer defensive end Eli Renick, and chat with coach Brad Spencer about what's next for North Central as they head to their sixth consecutive Stagg Bowl. Plus, for Johns Hopkins, what does this run ending mean for the state of the program? And for John Carroll, it's the end of two years where Nick Semptimphelter was able to play football for the Blue Streaks with tight end Terrence Rawls, who was not just his high school teammate, but a literal member of his family. He talks about that, and coach Jeff Behrman talks about Semptimphelter. Patrick and Greg also hand out game balls and we take your questions in the mailbag. That and more in this edition of the D3football.com Around the Nation podcast. The D3football.com Around the Nation podcast is a weekly conversation about NCAA Division III football, and has been running since 2007.

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Shai Rozen, MD, discuss the following articles from the January 2026 issue:   "The Efficacy of Flap Debulking after Facial Reanimation Surgery to Enhance Facial Symmetry" by Weiss, Fricke, Hohenstein, et al.   "The Natural Progression of Synkinesis" by Rail, Bhatia, Dragun, et al.   "Extended Sural Nerve Harvest: A Technique to Gain Additional Graft Length" by Millesi, Gates-Tanzer, Felzen, et al.   Special guest, Shai Rozen is Professor and Vice-Chairman in the Department of Plastic Surgery at the University of Texas Southwestern Medical Center and Director of the Facial Reanimation Program, specializing in treating patients with facial paralysis. He completed both general surgery and plastic surgery training at Johns Hopkins, followed by fellowships in both craniofacial and peripheral nerve surgery.    READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJan26Collection   The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello protest Vinjay Prasad, head of CBER FDA Nov memo stating administration of the COVID-19 vaccine resulted in 10 children's deaths, but are cautiously delighted by the December memo from those in CBER who dispute this data-less claim, how in 31 states pertussis vaccination rates have declined before Dr. Griffin then deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, of clinical outcomes of oseltamivir versus baloxavir for treating influenza infection, number deaths associated with COVID-19 hospitalizations and disease associated economic burden, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, how the German government is committed to research into long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Industry laments Prasad vaccine memo (Politico) Scoop: FDA vaccine chief's memo cited 10 pediatric Covid-19 vaccine deaths—but the agency's own analysis found 0–7 (Inside Medicine) Whooping cough cases soar as vaccination rates drop (NBC News) Marburg Outbreak in Ethiopia: Current Situation (CDC: Marburg Virus Disease) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles(CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Hundreds quarantined as South Carolina measles outbreak accelerates (Washington Post) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) In call with clinicians, CDC recommends flu vaccines widely (CIDRAP) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) Comparison of clinical outcomes of oseltamivir versus baloxavir in outpatients with influenza: a retrospective cohort analysis (International Journal of Infectious Diseases) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Effectiveness of 2024–2025 COVID-19 Vaccines in Children in the United States — VISION, August 29, 2024–September 2, 2025 (CDC:MMWR) Mortality following recovery from COVID-19 hospitalization: A long-term cohort study (International Journal of Infectious Diseases) COVID hospitalization tied to 69% higher risk of death for up to 2 years (CIDRAP) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Comparison of work productivity losses in the United States among employees with COVID-19 at high-risk of severe disease who were untreated or treated with nirmatrelvir/ritonavir (Journal of Medical Economics) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Long-COVID research just got a big funding boost: will it find new treatments?(Nature) Reaching out to US house representative Letters read on TWiV 1280 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Send us a textWhat if the most powerful tool on a crisis scene isn't a badge or a diagnosis, but a practiced partnership? We continue our conversation with Dr. Sarah Abbott about co-response and unpack how pairing clinicians with police changes the outcome of calls involving mental health, substance use, and high-stress events—from domestic incidents with kids present to house fires and welfare checks where information is thin.We trace the arc from a pioneering certificate at William James College to statewide intensives built on scenario-based, hands-on training. Instead of chasing labels, the curriculum teaches behavior reading, de-escalation under pressure, and language that preserves dignity while lowering risk. We dig into veterans' mental health and firearm culture, highlighting lethal means safety training that helps clinicians speak credibly about storage, temporary transfer, and time-limited access without shaming or seizing. A vivid field story shows how clear communication with dispatch and officers can soften the room, protect everyone on scene, and build trust that lasts past one call.The conversation widens to where co-response goes next. Through Abbott Solutions for Justice and the International Co-Responder Alliance, these practices are spreading across states and overseas, with growing momentum on college campuses that function like small cities. We explore why campus police and clinicians need shared playbooks, how programs like Johns Hopkins are leading, and what it takes to turn skepticism into skill—consistently, respectfully, and at scale. If you care about first responder wellness, community safety, and practical tools that work at 2 a.m., this is your roadmap for doing crisis response better.Subscribe for more conversations on co-response, first responder mental health, and practical de-escalation. Share this episode with a colleague who needs these tools, and leave a quick review to help others find the show.To reach Sarah, please visit her website at: https://www.abbottsolutionsforjustice.comSarah can also befound on LinkedIn at: https://www.linkedin.com/company/abbott-solutions-for-justice-llc/?viewAsMember=trueFreed.ai: We'll Do Your SOAP Notes!Freed AI converts conversations into SOAP note.Use code Steve50 for $50 off the 1st month!Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showYouTube Channel For The Podcast

Food as Medicine: Dr. Elizabeth Klodas – Disrupting Cardiology with Clinical Nutrition Join us as we explore a critical question: What if the solution to America's number one killer isn't in the pharmacy, but in the kitchen? Today's guest is Dr. Elizabeth Klodas, a Mayo Clinic and Johns Hopkins-trained cardiologist who founded Step One Foods after realizing that doctors, including herself, weren't addressing the most powerful intervention for heart disease diet. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Frank & JB preview the 2025 D3FB Semifinals, looking in-depth at both games: Johns Hopkins at UW-River Falls & John Carroll at North Central - with guests focused on the second game — JCU Gr. QB Nick Semptimphelter & NCC Sr. DL J.P. Sullivan join us. They also continue the Playoffs Guest Analyst segment, this week with ESPN Color Commentator Ryan Cavanaugh, who will be on the JCU/NCC broadcast with Anthony Lima Saturday at 4:30pm EST. Watch & enjoy the preview to both of these exciting games!

#5 ranked Johns Hopkins WBB head coach, Rodney Rogan joins this week's episode of @Notevend2 . JHU looks like one of the best teams in the country holding a perfect 8-0 record. In just two years, Rogan and JHU have now won back-to-back Centennial Conference Championships and made multiple Sweet 16 appearences. Rogan has now won at two different schools- beginning at his first head coaching opportunity at Rhodes College. Rogan led Rhodes to three straight Southern Atlantic Athletic (SAA) championships leaving with a 67-28 (.705) record. This pod talks about his process of getting to JHU, what the expectations are for the 2025-26 season, and the background of Rogan getting into coaching women's basketball. This episode is available wherever you get your podcasts. Follow/subscribe to @Notevend2 for more sports content! Enjoy the episode ...

About Mary Varghese Presti:Mary Varghese Presti is a transformational healthcare leader with over two decades of experience spanning clinical care, federal reform, biopharma, and health technology. As Corporate Vice President of Microsoft Health & Life Sciences, she drives growth in complex environments by creating clear strategy, aligning organizations, and operationalizing execution with discipline. Her prior roles include leading Nuance's Dragon Medical business, overseeing IBM Watson Health's Life Sciences portfolio, incubating new ventures at athenahealth, and driving digital-health transformation at Pfizer. She began her career as a pediatric nurse at Johns Hopkins and later helped shape national health IT and payment reforms at Booz Allen. Known for navigating complexity with optimism and rigor, she consistently turns ambiguity into strategy and strategy into measurable results.Things You'll Learn:AI in healthcare is evolving from simple assistants to agentic services that can independently execute predictable workflows, allowing clinicians to regain time and focus. This shift enables a hybrid workforce where human and digital colleagues work side by side.Dragon Copilot for nurses was designed specifically to support the way nurses document care, capturing structured inputs such as vitals, intake/output, and observations through natural speech. By reducing EHR time and ambiently recording bedside interactions, it helps turn “caring out loud” into complete documentation.Nurses spend more than a quarter of their 12-hour shifts documenting in the EHR, often feeling emotionally torn between screens and patients. AI that listens in the background can significantly reduce this burden while allowing for more presence at the bedside.New tools are starting to expose the “invisible work” nurses perform, from constant micro-assessments to coordination with ancillary departments. Making this work visible is a critical step toward properly valuing nursing labor and improving workforce planning.Real-world use cases, such as AI agents assembling data for tumor boards at academic centers, show that agentic workflows can compress decision timelines from weeks to days. These same principles can be extended to many clinical and non-clinical tasks, accelerating care while preserving clinician judgment.Resources:Connect with and follow Mary Varghese Presti on LinkedIn.Follow Microsoft on LinkedIn.Visit the Microsoft and Life Sciences website.Listen to Mary's previous interview on our podcast here.Watch Mary's keynote presentation at the HLTH conference here.

Head Coach Matt Walker joined Vineeta to discuss Saturday's Semifinal matchup with Johns Hopkins at home in the elements! Plus, listen to the thing that has made him ultra famous among fellow coaches! Good luck coach Walker and the Falcons!

Most practices are busy—but busy doesn't always mean profitable. In this episode of Sharkpreneur, Seth Greene interviews Terri Ross, Founder of Terri Ross Consulting & Co-Founder of Aesthetic Success, who is one of the leading voices in the medical aesthetics industry. With nearly two decades of experience, she has advised top practices, trained thousands of providers, and been featured as a speaker at Johns Hopkins, international conferences, and in multiple publications. In this conversation, Terri shares her proven seven-pillar revenue optimization system, insights on KPIs that drive millions in growth, and strategies to help practices thrive in competitive markets. Key Takeaways: → Why being busy doesn't guarantee profitability. → The seven-pillar framework for revenue optimization. → Common mistakes most practice owners make—and how to avoid them. → The KPIs that matter most in the first 3–6 months. → How pricing and compensation strategies impact profitability. Terri Ross, founder of Terri Ross Consulting, is a globally recognized expert in practice management and high-performance sales coaching, with a specialization in medical aesthetics. She has helped practices and Fortune 500 companies achieve over $2.5M in annual revenue growth. Industry leaders like Galderma, Skinbetter, and Merz Canada rely on her expertise for training sales teams and delivering keynote presentations at top aesthetic conferences. As the founder of Terri Ross Consulting, she later launched the APX Platform, merging with a patient education firm in 2023 to form a cutting-edge performance system. With a background in sales leadership roles with Fortune 500 medical device companies, Terri consistently ranked in the top 10% nationally. Terri hosts the "In Touch with Terri" podcast and co-founded Aesthetic Success, a quarterly summit series designed to master business strategy in aesthetics. Connect With Terri Ross: Website: https://terrirossconsulting.com/ Instagram: https://www.instagram.com/terrirossconsulting/ LinkedIn: https://www.linkedin.com/in/terriross/ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode Bill interviews Dr. John Gartner, a former Johns Hopkins professor and founder of Duty to Warn. In his return to the Bill Press Pod, Dr. Gartner provides an in-depth analysis of President Donald Trump's cognitive health, asserting that Trump exhibits signs of severe cognitive decline and personality disorders such as malignant narcissism. He discusses specific instances that showcase Trump's deteriorating mental state, including erratic behavior, memory lapses, and lack of empathy. The episode delves into the challenges and dangers posed by Trump's mental condition, its implications on his presidency, and potential future scenarios.Today Bill once again highlights the work of Chef Jose Andres' World Central Kitchen. While the Trump administration is decimating America's soft power around the world, and our role as a provider of aid to people and countries in peril, the World Central Kitchen goes where they're needed. No matter the war zone nor the danger of a natural disaster. This is one of Carol and my favorite charities and I hope you'll support them at WCK.orgSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

George Kikvadze is the Founder of Cryptic8 VC, investing at the intersection of technology and longevity. He is also Vice Chairman and an early backer of Bitfury Group, the company at the heart of this book. A Bitcoin pioneer since 2013, he was privileged to be behind three tech unicorns - Bitfury, Cipher Mining, and Hut 8 - with a combined value exceeding $12 billion. A graduate of Wharton and Johns Hopkins, George enjoys tennis, chess, and raising his two sons. Bill Tai has funded startups since 1991, with 23 becoming publicly listed companies. An early backer of Zoom, Canva, and Dapper Labs, he also co-founded data pioneer Treasure Data (acquired by SOFTBANK) and IPInfusion (TSE:4813). Originally a chip designer at LSI Logic and Taiwan Semiconductor, he later led semiconductor IPOs at Alex Brown & Sons. He holds a BSEE from the University of Illinois and an MBA from Harvard, where he advises the Dean. He chairs ACTAI Global, uniting entrepreneurs and innovators for tech-based conservation. Learn about the inside story of Bitcoin in this great new book, And Then You Win: A Start-Up's Untold Story of Grit, Grind, and Glory Anthony Scaramucci is the founder and managing partner of SkyBridge, a global alternative investment firm, and founder and chairman of SALT, a global thought leadership forum and venture studio. He is the host of the podcast Open Book with Anthony Scaramucci. A graduate of Tufts University and Harvard Law School, he lives in Manhasset, Long Island.

Fruit baskets don't cure burnout. Neither do yoga apps. Dr. Richard Safeer explains why most wellness programs flop, and how leaders can build cultures of health that actually stick. He shares why well-being belongs in the strategic plan, not the suggestion box, and how six building blocks – peer support, leadership engagement, connection points, norms, values, and social climate – turn good intentions into everyday behaviors. You'll hear stories from Johns Hopkins where small shifts (blood pressure wins, manager training, even better cafeteria choices) stacked up to big cultural change. This isn't about adding another program. It's about making well-being who you are as a company, not what you do once a year. Website: https://richardsafeer.com, http://creatingawellbeingculture.com LinkedIn: https://www.linkedin.com/in/richardsafeer Book: A Cure for the Common Company: https://amzn.to/3bG1q1D Timestamps 00:00 Intro 03:30 Why Wellness Programs Flop (and What Works Instead) 05:56 Well-Being in the Strategic Plan, Not the Perks List 09:42 Leaders as Mood Mirrors: Why Your Energy Spreads 13:24 Building Health into Systems, Not Side Projects 15:10 Johns Hopkins Story: From Program to Culture Shift 17:32 Small Wins: Blood Pressure, Breathing, Better Choices 19:34 Why Work Can't Ignore Well-Being Anymore 21:27 Core Values Matter (If You Actually Live Them) 24:28 The Six Building Blocks of a Healthy Company 29:00 Making Well-Being Everyday, Not Seasonal

From college dorms to quiet suburbs, fentanyl's reach no longer fits a stereotype. This week on Pathology with Dr. Priya, a Zone 7 series, Sheryl McCollum and Dr. Priya Banerjee confront the reality of a Providence College house party that nearly claimed seven young lives. Together they discussed the chemistry, economics, and criminal psychology behind modern synthetic drugs, showing how a single white powder can conceal a fatal mix, and how dealers prioritize profit over safety. These drugs do not discriminate; they affect every community, every family, and every socioeconomic group. For parents, this episode serves as a reminder that prevention begins long before a crisis. Awareness, honest conversation, and early education remain the most powerful safeguards against tragedy. Highlights • (0:00) Welcome to Zone 7’s Pathology with Dr. Priya: “’Tis the season”: why overdoses spike between Thanksgiving and New Year’s • (0:45) Seven Providence College students found unresponsive at a house party • (3:00) Fentanyl's evolution from heroin corridors to every college town in America • (5:00) Cutting agents and chemical roulette: what's really in the “white powder” • (7:00) Xylazine, ketamine, and the rise of “zombie drugs” and clandestine labs • (11:15) Dealers, profit, and the deadly absence of quality control • (12:30) "Drugs don't discriminate": how overdose affects every class and community • (16:30) As holiday parties ramp up, Sheryl and Dr. Priya address alcohol, impaired driving, and false confidence behind the wheel• (18:15) “There ain’t a drug dealer out there that cares about anybody they’ve ever sold to”: how profit drives addiction across every demographic • (22:15) Final reflections: stay aware, stay connected, and keep the season focused on life, not loss About the Hosts Dr. Priya Banerjee is a board-certified forensic pathologist with extensive experience in death investigation, clinical forensics, and courtroom testimony. A graduate of Johns Hopkins, she served for over a decade as Rhode Island’s state medical examiner and now runs a private forensic pathology practice. Her work includes military deaths, and high-profile investigations. Dr. Priya has also been featured as a forensic expert on platforms such as CrimeOnline and Crime Stories with Nancy Grace. She is a dedicated educator, animal lover, and proud mom. Website: anchorforensicpathology.com Twitter/X: @Autopsy_MD Sheryl “Mac” McCollum is an active crime scene investigator for a Metro Atlanta Police Department and the director of the Cold Case Investigative Research Institute, which partners with colleges and universities nationwide. With more than 4 decades of experience, she has worked on thousands of cold cases using her investigative system, The Last 24/361, which integrates evidence, media, and advanced forensic testing. Her work on high-profile cases, including The Boston Strangler, Natalie Holloway, Tupac Shakur and the Moore’s Ford Bridge lynching, led to her Emmy Award for CSI: Atlanta and induction into the National Law Enforcement Hall of Fame in 2023. Email: coldcase2004@gmail.com Twitter/X: @ColdCaseTips Facebook: @sheryl.mccollum Instagram: @officialzone7podcast

It's a milestone podcast, but we're not quite to the final stage of the Division III football season. You can't blame us for getting dressed up -- OK, maybe just Greg decided to dress up for the audio podcast. But answering the call to the Final Four ball were who most people thought they were in our predictions this week: Johns Hopkins, John Carroll, North Central and UW-River Falls. And instead of doing the blow-by-blow of each game -- because, let's be honest, the average margin of victory was nearly 20 points -- let's hear from people in the middle of each of these games. So we'll be joined by John Carroll cornerback Dylan Crasi, who spent the first half on the sidelines but made his presence known right away in the third quarter. We'll talk to North Central quarterback Garet Wilson, whose first year in Division III since coming from Oklahoma State has been a revelation for both Division III and for him. We chat with UW-River Falls coach Matt Walker about the schematic and playbook choices the Falcons made this week, how they kept players warm (seriously, there was a detailed plan). And Keith McMillan talks to Johns Hopkins offensive lineman Michael Nwosu and defensive lineman Graham Hodge about their play on a day where the Blue Jays' line play was huge. Plus, the coaching carousel continues to turn as Ithaca loses a second consecutive coach to the Ivy League. Sewanee makes a hire who has much more D-III experience than the last guy they hired. And Lawrence didn't even give its new coach six months before cutting him loose?  Patrick and Greg also hand out game balls and we take your questions in the mailbag segment, and Patrick gives an early Stagg Bowl prediction? That and more in this edition of the D3football.com Around the Nation podcast.

"I learned that life is not about me, my success, or my wins. It is about service." James Harris Jr., MDThis Earth Xperience explores faith, survival, purpose, and the long road from fear to service. James Harris Jr., MD shares his story of growing up in poverty, being raised by his grandmother in a dangerous environment, and navigating fear in a home that never felt safe. He speaks openly about childhood trauma, gang involvement, and the mindset of survival that shaped his early decisions.James reflects on the near death experience in college that forced him to confront his past and the weight of choices he had never repented from. That moment, paired with a campus Bible study, became the turning point that shifted his direction. He explains how fear once drove his behavior and how faith later gave him clarity, responsibility, and purpose.The conversation moves through marriage, long suffering, and love shaped by sacrifice. James shares the realities of becoming a teenage father, staying married for over three decades, and walking through tragedy as a family. He speaks in detail about his son Marcus's life altering accident, the pressure of being both surgeon and father, and the grief he buried in order to survive. He reflects on how faith sustained him when logic, control, and professional skill were no longer enough.James also shares how service reshaped his understanding of love, from caring for patients to serving refugee communities abroad. He challenges the idea that happiness comes from possessions or achievement and instead points to joy rooted in purpose, faith, and compassion. His story reframes success as obedience, humility, and the willingness to help others even when life feels unfair.Each Earth Xperience has its own fingerprint, shaped by the life of the guest. The X represents whatever we explore together. In this episode, the X is an Experience with James Harris Jr., MD, a general surgeon at Johns Hopkins, associate professor of surgery, residency program leader, husband, father, and man of faith. He is currently working on a memoir that explores identity, resilience, and what truly makes a human.You can learn more about his story and read sample chapters of his memoir at jamesharrisjrmd.com. You can also find him on Instagram at @jamesharrisjrmd.Questions to reflect on• What fears shaped the way you learned to survive?• When did faith become more than belief and turn into action?• How do love and sacrifice show up in your closest relationships?• What grief have you buried in order to keep functioning?• How do you define success when life strips away control?• What does service look like in your everyday life?• If everything you owned disappeared, what would still give you joy?

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss the rise in norovirus infections, contamination of infant formula and botulism outbreak, confusion and response to the CDC's ACIP decision to reverse the recommendation for a birth dose of the hepatis B virus vaccine and how states in the Northwest and Northeast are responding as well as some insurance companies, then deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, South Carolina's imposed quarantine of individuals due to their accelerated measles outbreak, neurotropism of H1N1, benefits of the RSV and COVID vaccines, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Norovirus season! (Wastewater Scan) Outbreak Investigation of Infant Botulism: Infant Formula (November 2025) (FDA: Foodborne illnesses) Botulism outbreak sickens more than 50 babies and expands to all ByHeart products (AP News) CDC advisers drop decades-old universal hepatitis B birth dose recommendation, suggest blood testing after 1 dose (CIDRAP) Health and Economic Benefits of Routine Childhood Immunizations in the Era of the Vaccines for Children Program — United States, 1994–2023 (CDC: MMWR) Universal Hepatitis B vaccination at birth: safety, effectiveness and public health impact (CIDRAP) Recommended Child and Adolescent Immunization Schedule for Ages 18 years or younger (American Academy of Pediatrics) West Coast health experts reject RFK Jr. panel, say hepatitis B vaccines at birth should continue (The Oregonian) Statement from the Northeast Public Health Collaborative In Response to ACIP's Hepatitis B Vote (NJ.Gov Health) Governors Denounce ACIP Recommendation on Hepatitis B Vaccination, Reaffirm Commitment to Strong, Evidence-Based Childhood Vaccination Programs (Governors Public Health Alliance) Blue Cross and Blue Shield Companies Statement on Vaccines (Blue Cross Blue Shield) AHIPStatement on Vaccine Coverage (AHIP) Pediatricians reject CDC advisers' guidance, plan to continue vaccinating all newborns against hepatitis B (CIDRAP) Survey: Social media on par with CDC as trusted vaccine source (Healio) FDA to investigate whether adult deaths linked to COVID vaccine (Washington Post) Exclusive: US FDA launches fresh safety scrutiny of approved RSV therapies for infants (Reuters) Marburg Outbreak in Ethiopia: Current Situation (CDC: Marburg Virus Disease) Contemporary highly pathogenic avian influenza (H5N1) viruses retain neurotropism in human cerebral organoids (OFID) Confirmations of Highly Pathogenic Avian Influenza in Commercial and Backyard Flocks (USDA: Animal and Plant Health Inspection Service) Indiana, cases of New World screwworm in Mexico, rising US flu activity (CIDRAP) Mexico reports 92 cases of myiasis in humans caused by screwworm (Expreso.press) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Hundreds quarantined as South Carolina measles outbreak accelerates (Washington Post) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Types of Influenza Viruses (CDC: Influenza (flu)) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Intensive Care Unit Stay and Mechanical Ventilation Among Adults with Respiratory Syncytial Virus-Related Hospitalization by Age and Comorbidity Status (Infectious Diseases and Therapy) Cardiovascular Events 1 Year After Respiratory Syncytial Virus Infection in Adults (JAMA: Open Network) Long-Term Illness in Adults Hospitalized for Respiratory Syncytial Virus Disease, United States, February 2022–September 2023 (CDC: Emerging Infectious Diseases) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis (LANCET: Infectious Diseases) Effectiveness of Nirsevimab in Preventing Respiratory Syncytial Virus-related Burden: A Test-negative Case-control Study in Infants With Bronchiolitis in Lombardy Region, Italy (The Pediatric Infectious Disease Journal) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Maternal and Neonatal Outcomes After Respiratory Syncytial Virus Prefusion F Protein Vaccination During Pregnancy (Obstetrics & Gynecology) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults Aged 18 to 59 Years in France (JAMA: Open Network) Two-year prognosis of mRNA vaccine-related myocarditis compared with historical conventional myocarditis: a population-based cohort study (CMI: Clinical Microbiology and Infection) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverageOptions (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1278 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

How can the United States advance its interests without abandoning its core values? Alexander Vindman, retired U.S. Army lieutenant colonel and former director for European Affairs on the White House's National Security Council, presents a discussion on the critical interplay between morality, values and power in the practice of geopolitics and national security.  After the collapse of the Soviet Union, six U.S. presidential administrations across both parties crafted policies for Russia, Ukraine and Eurasia that unintentionally emboldened Russia and played into its imperialist, centuries-long mythos of regional hegemony, by pursuing short-term transactional policies. The result: military aggression and full-scale invasion. It was all too foreseeable.  Vindman will discuss the shifting U.S. foreign policy landscape, what a just peace and lasting end to the war in Ukraine might look like, the administration's increasingly transactional approach to international relations, and Trump's heavy-handed approach to national security and domestic politics. About the Speaker  Dr. Alexander Vindman, a retired US Army Lieutenant Colonel, was the director for European Affairs on the National Security Council. Before that, he served as the political-military affairs officer for Russia for the chairman of the Joint Chiefs of Staff and as an attaché at the U.S. Embassies in Moscow and Kyiv. While on the Joint Staff, he authored the National Military Strategy for Russia. He earned a Master's from Harvard University, where he served as a Hauser Leader, and a Master's and Doctorate from Johns Hopkins, where he is a senior fellow. Dr. Vindman leads the national security think tank Institute for Informed American Leadership, is the president of the nonprofit Here Right Matters Foundation, an executive board member for the Renew Democracy Initiative, a senior fellow at the Kettering Foundation, and a senior advisor to VoteVets. Dr. Vindman is the author of the "Why It Matters" Substack and the New York Times bestselling books Here, Right Matters and The Folly of Realism. Learn more about your ad choices. Visit megaphone.fm/adchoices

"It's recommended that everyone over the age of 40 go see their eye doctor once a year." -Dr. Rudrani Banik   Dr. Rudrani "Rani" Banik is a renowned board-certified neuro-ophthalmologist and an integrative medicine specialist based in New York City. She holds the position of Associate Professor of Ophthalmology at Mount Sinai and has an impressive educational background, including an MD from Brown University, a residency at UC Irvine, and a fellowship at the Wilmer Eye Institute at Johns Hopkins. Dr. Banik adopts a holistic approach to eye health, focusing on nutrition, lifestyle, and supplementation. She is also a prolific author and media expert, featured on platforms like Good Morning America, NBC, and The New York Times. Episode Summary: Join host Jana Short in an engaging conversation with Dr. Rudrani "Rani" Banik, renowned neuro-ophthalmologist and integrative medicine specialist, as they delve into the intricacies of eye health and holistic wellness. In this enlightening episode, Dr. Banik shares her personal journey with chronic daily migraines, which led her to discover the powerful potential of lifestyle and dietary changes in managing health conditions. With a foundation in conventional medicine, she transitioned to a more integrative approach, emphasizing the importance of diet, stress management, and functional medicine in overall well-being.   Throughout the episode, Dr. Banik discusses her innovative work in eye health, emphasizing the role of nutrition and supplements in maintaining optimal vision. She elaborates on the extensive array of nutrients, beyond the well-known carrots, that contribute to eye health, such as lutein and zeaxanthin. Her insights extend to the necessity of regular eye examinations and lifestyle adjustments to protect and preserve ocular health. Dr. Banik also introduces her supplement line, Ageless by Dr. Rani, and her book, "Beyond Carrots," showcasing her dedication to educating others on the significance of holistic eye care.   Key Takeaways: Dr. Rani Banik's journey with chronic migraines led her to embrace integrative medicine, highlighting the impact of diet and lifestyle on health management. Regular eye checkups are crucial, as the eyes can reveal early signs of over 200 medical conditions. Beyond carrots, nutrients like lutein, zeaxanthin, and meso-zeaxanthin are vital for eye health, acting as internal sunglasses and blue blockers. Incorporating diverse foods, such as leafy greens, bell peppers, and spices, can significantly reduce the risk of eye diseases. Supplements should complement a healthy diet, filling in nutritional gaps due to factors like dietary absorption or soil nutrient depletion.   Resources: www.drranibanik.com https://www.facebook.com/rudrani.banik.2025/ @‌dr.ranibanik https://x.com/RudraniBanikMD     ✨ Enjoying the show? Stay inspired long after the episode ends! Jana is gifting you **free subscriptions to Ageless Living Magazine and **Best Holistic Life Magazine—two of the fastest-growing publications dedicated to holistic health, personal growth, and living your most vibrant life. Inside, you'll find powerful stories, expert insights, and practical tools to help you thrive—mind, body, and soul.  

Can a digital replica of your heart save your life? In CXOTalk episode 902, Michael Krigsman talks with Dr. Joe Alexander, Director of the Medical and Health Informatics Lab at NTT Research, to explore the revolutionary world of Bio-Digital Twins.Discover how researchers are using mathematical modeling to build "computational replicas" of the human cardiovascular system. Dr. Alexander explains how these digital twins can predict heart failure, automate critical care in the ICU through closed-loop intervention systems, and pave the way for a future where personalized medicine is accessible to everyone.We dive deep into the science of treating the heart as an electrical circuit, the ethics of AI in medicine, and the "moonshot" goal of eliminating cardiovascular disease..

When the previous "biggest win in school history" is from the 1950s, replacing the entry at the top of the list means something.  Sure, you could quibble over whether a win against Syracuse from seven decades ago, or a national quarterfinal win at Brockport in 2002, or a quarterfinal win at UW-Whitewater in 2016 should be next on the list, but no regular season win, even one against Mount Union, compares with beating Mount Union at Mount Union in the playoffs.  A win of this nature is so iconic that the head coach's phone blows up, and so does the feed of everyone else even remotely associated with John Carroll football. The traffic on D3football.com nearly doubled in the course of 10 minutes. There's no pretending this is an ordinary win. And to John Carroll's credit, they didn't try to. We chat with Jeff Behrman, the JCU head coach, about having confidence in kicker Colin Schuler after a missed chip shot in the first overtime nearly cost them the game, about the key final play of the game, and about the team's return to campus, the reception, and what's next for the Blue Streaks. We bring back in former co-host Keith McMillan to break down the play, what he saw on video from his perspective as a former Division III football starting safety.  Mailbag questions came hard for this game. The one we chose to answer was whether this means that JCU is up to Mount Union's level or if Mount Union has slipped and there's just one elite team. The answer is perhaps no different than it was when Keith and Greg Thomas wrote a column under the headline "Today, we are all Mount Union" after the 2022 Stagg Bowl, for we are all chasing North Central. We take your mailbag questions. We have postgame audio from all eight games and break them all down. Keith also sits down with Johns Hopkins coach Dan Wodicka and safety Sam Bourdo. Bethel's David Geebli talks about recovering from fumbling on the first snap of the game. Susquehanna's Josh Ehrlich takes the blame for the River Hawks' slow start. Matt Walker talks about UW-River Falls' slow start, although it was fairly brief. Jesse Scott talks about what they saw that was familiar in DePauw's run defense. Berry safety Chaz Pope talks about his game-sealing interception. There's those clips and much more in this podcast. Plus we drop some scoop as to when we will release our All-America team, we answer whether we really thought Johns Hopkins lost some shine after the F&M loss and we bring the receipts to prove it (they're all on the website).  Patrick and Greg also hand out game balls, bring you through the stats of the week and we take your questions in the mailbag segment. That and more in this edition of the D3football.com Around the Nation podcast.

Dr. Pedro Barata and Dr. Ravin Garg discuss strategies to increase trial representation, including leveraging trial navigators and prioritizing pragmatic trial models, as featured in the ASCO Educational Book article, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care." TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast from ASCO featuring compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I am a medical oncologist at University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I am also the associate editor of the ASCO Educational Book. We know that in recent years, the oncology community has increasingly prioritized the need to modernize clinical trial eligibility, reduce patient burden, and enhance diversity in trial participation. On that note, today we will be speaking about ways to enhance access to clinical trials with Dr. Ravin Garg. He is a hematologist oncologist at Maryland Oncology Hematology and also an assistant professor of oncology at Johns Hopkins Hospital in Baltimore. Dr. Garg is also the co-author of a fantastic paper in the ASCO Educational Book titled, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care."  Dr. Garg, welcome. Thanks for being here, and congrats on your paper. Dr. Ravin Garg: Thank you for having me, Pedro. I am excited to be here. Dr. Pedro Barata: [KI1]  Your paper is a wonderful, multidisciplinary piece that actually features perspectives from the different stakeholders, right? The patient advocacy, industry, community practice, and academia about these challenges in making trials more available. This podcast is a wonderful platform. It reaches out to a lot of folks within our community. So, I will start by asking you the obvious. Why do you think it is a must read for our community, for our listeners? Dr. Ravin Garg: So Pedro, thanks again for inviting me. You do a great job with these podcasts.  So, I think first and foremost, oncologists right now are under a lot of stress, just in terms of clinical volume. There is concern for research money, and how we get the best care for our patients. So I think this article is very important because it helps bring together, as you had mentioned, the stakeholders throughout academic to community practice and everywhere in between, and try to find how, as a team with different oncologists who partake in different aspects of oncology, can come together to streamline the process to try to get our patients on trials, or certainly have them have availability of trials, just if they are interested in going on them. Being in practice, we have had several challenges that we can talk about throughout this podcast, but I think it is a very important paper because it recognizes that at the end of the day, it takes a team effort for all of us in academics, community, industry, and pharmaceuticals to really come together as a team to really help put forth the trials for our patients. Dr. Pedro Barata: So, from the perspective of a community oncologist, how do you put together, or maybe you can describe some of the challenges that you see to increase trial participation in the community? Dr. Ravin Garg: Yes, Pedro, that is a great question, and it is something that I keep on thinking about and trying to find ways to be better at it myself. But I will say some of the challenges as a community doctor that I have seen for myself and talking to other colleagues. Number one, I do think there is a lot of stress on doctors in the community in general, Pedro. Oftentimes we are tasked to see a wide smorgasbord of patients, so we may not have the luxury of being a specialist in any particular tumor subtype. Like oftentimes, we will have to see lung cancer, the next one will be breast cancer, the next one could be CML, the next one could be thrombocytopenia. And as you know better than I do, Pedro, the field in each one of these disciplines is changing so rapidly: molecular genomics, radioligand treatments, different imaging tests, MRD testing for some of our hematologic malignancies. And I think one challenge we have in community is just keeping up with the basics of Oncology 101. In the process of doing that, it can be very difficult to sometimes remember that we have very exciting trials available for our patients. So, I think a lot of it is the day in and day out of being an oncologist is so taxing at times that oftentimes a research trial is not the first thing in our head space when we see a patient. I think number two, Pedro, at least in the community, and perhaps this is with academics too, is that we are bombarded, I would say, by a lot of messaging these days. We have in-baskets to go through, labs to go through, things of that nature. And in the process of a patient visit, seeing them, doing an exam, taking a history, trying to go over the NCCN guidelines on best practice for how to manage their care, at least for me at times, it is very hard to remember, "Hey, there might be a great trial available, whether within our network or maybe partnering with an academic center." So getting through a day can be fraught with a lot of peril and just difficulties, I would say. And I would say number three, Pedro, at least as, you know, I am in a private practice where I do see a wide range of benign and malignant hematology and solid tumors, so I would not call myself a specialist. And I think the challenge with that, at least for trials, Pedro, is that when you are a specialist or perhaps you are focusing on a couple of disease subtypes, you become more of an authoritative voice in those types of tumors, and you might be more aware of the trials within your network or perhaps in proxy with an academic center that you can offer your patient. So I think when sometimes we spread ourselves too thin, it can be very hard to be a thought leader, if you will, in a particular subtype of a malignancy, let's say, and maybe not be aware of a trial that could be really well-suited for your patient. In terms of ideas that myself and colleagues have had in terms of helping mitigate against some of these, I would say, setbacks or issues in the practice for trial enrollment, some of the things we have talked about, Pedro, is, number one, is we do partner with academic centers. So we live here in Maryland. We have several really fantastic academic centers. So, you know, oftentimes, not just within our practice of Maryland Oncology Hematology, we have a lot of great trials available here too, for certain, but in addition to that, we will often times work with doctors at Georgetown, Johns Hopkins, and Maryland if they have a compelling trial that we do not have within our network. It is really of the patient's interest, Pedro, to reach out to them in a collaborative manner to see if they have a trial that might be really compelling for your patient. So I do find myself collaborating a lot with colleagues in, like talented like yourself in academics. You know, I think you do a lot of GU malignancies. So as an example, like partnering with colleagues who are GU experts and say, "Hey, we have a patient with stage IV renal cell. These are the standard options I know, but are there any trials that you might have available?" I think the other thing that has been very helpful for us is having navigators within research, Pedro. Like as an example, what has really helped the uptake of trial enrollment for our center in Annapolis is having a research navigator because often times what they can do is, a priori, Pedro, before you see the patient and you are kind of formulating a standard of care treatment plan perhaps, they might tug you on the shirt and say, "Hey, we have a great trial here through Sarah Cannon, or there might be something else out there." And being aware of that when you go into a patient's room really provides a nice arena, if you will, to go and say, "The standard of care is here, but hey, we have a trial option that might be well suited for you, maybe perhaps even better, that we can talk about, too." So having research support in the community is really a huge boon, I think, Pedro, for us to really increase our enrollment for patients onto trials. Dr. Pedro Barata: Yes, I really love that, Ravin. So, let me switch gears a bit. I would love for you to talk a little bit about patient advocacy because they do play a huge role in cancer, and they address many barriers. How do you think we should leverage the patient advocacy groups to reduce patient burden and maybe have them really leverage patient advocacies to improve representation in clinical trials? What do we think we can do more? Dr. Ravin Garg: Oh, Pedro, I think they are very critically important. As a clinical oncologist now, and I would say this is for anyone in the field of medicine, you are exactly right. I think patients are bombarded by information. There are a lot of things online, whether it be TikTok, Facebook, Google, Yahoo, and people really just have a lot of information given to them. And some of it is fact driven, and some of it is not, Pedro. And oftentimes, I do think there can be at times a mistrust with some medical personnel. I think we are in an era where we are seeing that to some degree with some attributes of medicine. And I think of it as an opportunity for education for the patient and for myself as a physician. And I think patient advocates, to your point, which was well taken, serve as a bridge to both. And what I mean is that, you know, patient advocates are wonderful. They are, I think, outstanding communicators. They almost are a neutral party, Pedro, where many patients feel that they are an independent source of information that is free of bias, if you will. They are there to provide support, emotional support, scientific support for patients so they can make an informed decision. So, in terms of our practice right now, patient advocates is something that we are evolving in that capacity, I would say, Pedro. I think now more than ever, having more people as bridges of communication with care providers along with patients is of critical importance. And I would venture a guess, and I think this has been published, where patient advocates really can help tremendously in familiarizing patients with trials and what they are all about and maybe clear up some misconceptions of what trials, what the mission of trials are. Because I do think some patients, at least I have had a few over the years, where when they hear the term trial, they almost think they are being experimented upon, when, in point of fact, they could really help advance their care. That messaging along the way for some can may be mixed up a little bit. And so I think patient advocates is a really great way to offer more information for patients with a source they find very independent and trustworthy, if you will. And it can really help expedite, and I think make a more fruitful conversation for care providers, whether academic or community, and they might be more open-minded in terms of enrolling onto a trial. Dr. Pedro Barata: Wonderful. Yes, I agree. I agree with you completely.  So let's focus a little bit now on the folks designing the studies. We usually call them the sponsors. It might be an academic sponsorship, if you will, but we can also have pharma being the sponsor of a study. The angle from an academic design, it is not necessarily the same as what happens when we have pharma. And from that angle, how do you think a more inclusive research can be promoted? Dr. Ravin Garg: Oftentimes with trials, I think keeping them simple, as simple as we can. And what I mean by that is, often times for trials, Pedro, even for care providers who are enrolling, it can be daunting when there are a lot of different things involved, particularly, let's say, for investigator sponsored, which are incredibly brilliant science, incredible, but it can be a little bit daunting for patients and even the referring physician to talk about getting translational specimens, imaging, traveling to certain centers to get scans and biopsies and even different diagnostic testing like PSMA testing for, you know, prostate cancer. And it can, I think, be very intimidating for patients in terms of what might be required of him or her to enter onto a trial. Like, "This is not what I signed up for. This is laborious. This is a full time job for me. Do I have to pay for parking to go to a city? Do I have to pay for these imaging tests? And do I have to stay in a place for my family to enroll onto a trial?" So I think keeping trials as simple as possible, but yet cull the data we need as investigators where we can really advance the care, hopefully get approval for a drug, but also learn more about the medication and how it works for our patients. So I think simplifying language for trial is very important. I know when I have gone over studies for patients, Pedro, if it is a voluminous amount of information, they can right away get very intimidated. "Like, oh my goodness, this is like a term paper for college again," you know? I am joking, but you know, keeping language simplified is very important, I think, number one. And I feel that sometimes when they are asked to do a lot of different diagnostic testing, which is very important for translational work, I 100% understand, but I do think sometimes patients can get a little bit off put, if you will, and frustrated with the whole process of doing it. The second thing for our patients, Pedro, that they have mentioned to us when we put them on trials, not just within our own site but elsewhere, is that it takes a lot of time in terms of collecting information, perhaps a washout period from their last standard of treatment prior to enrollment onto a study. Many patients, Pedro, as you know better than I do, are in maybe crisis in terms of their health and their cancer might be growing, promulgating out of control, and they worry about not being able to expeditiously start onto a treatment, onto a trial. So that can lead to a lot of frustration. And one thing that you brought up, which was outstanding for me, is the enrollment criterion for some of our patients is felt to be somewhat strict. We have had some patients who may have had a remote history of a stage I malignancy that was by all accounts in remission, you know, let's say 4 or 5 years in the past, and the risk of recurrence at this point would be incredibly low, but they may not be able to enter onto a study because of some stringent criterion put forth. And that can be a little bit frustrating. In fact, I have had one or two patients who, as an example, with kidney issues, but the GFR was about 60, like right near a cutoff that oftentimes, as you know, we use where you can get into trial or not. And you know, if they are at 58, as an example, and otherwise they are a picture of health, a great candidate for a trial that will likely advance their care, and if the entry criterion is too stringent, that might be a lost opportunity for all parties involved, all stakeholders, if you will. I do appreciate the criterion for entry onto studies cannot be too liberalized. You have to have a certain baseline, but there is a little bit of a gray area and tension, of sorts, if you will, where the patient has a comorbid illness that is a disqualifying offense, but in practicality, perhaps it shouldn't be, especially if they are motivated and there is an opportunity to really advance their care. We have run into, not often, but sometimes in the past, I should say, where patients have been very off put because we try to get them onto a study and there may have been a particular feature or attribute in their underlying care that they couldn't get onto it. So I think having a little bit more thoughtfulness, perhaps, in terms of entry criterion and practicality, if you will, I think would really help enrollment onto studies. Dr. Pedro Barata: Really well said. Is there anything else that you would like to tell our listeners before we wrap up the podcast today? Dr. Ravin Garg: I would say just macroscopically speaking, it is really an honor to be an oncologist. I think I speak for both of us. Anyone listening who is thinking about the field, it is tremendous. Just the research, the bravery of our patients, and the thoughtfulness of our scientists like Pedro and translationalists and clinical trialists is really awe inspiring. So I have really loved this field. I will say from a trial perspective, we really need to enter as many patients as we can onto trials because the science is so brilliant now, the genomic underpinnings of the tumor, we are making great strides as a team of clinicians and scientists, translationalists. So the more that we can get people onto trials and get approved drugs, it is going to help them out in the end. So I think it is such an important time for all of us to come together as a community, find the best way to help our patients out. And clinical trials have to be at the forefront of how we can continue to advance care for our patients. Dr. Pedro Barata: Yeah, no Ravin, I really agree with you. We really need to increase access to clinical studies, and actually your paper is a great step in that direction by raising awareness, bringing up solutions, and again, collaboration, collaboration, collaboration is really a multidisciplinary effort to accomplish that.  Thank you so much for sharing your fantastic thoughts and insights with us. Dr. Ravin Garg: Thank you, Pedro. I am- you do a wonderful job with these podcasts. I am really honored to meet you and to be part of this. Dr. Pedro Barata: And thank you to our listeners for your time today. I encourage you to check out Dr. Garg's article in the 2025 ASCO Educational Book. We will post a link to the paper in our show notes. And please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ravin Garg Follow ASCO on social media:          @ASCO on X      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn       Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ravin Garg: Patents, Royalties, Other Intellectual Property: Creator, editor, and writer of hemeoncquestions.com  

In this deeply personal and inspiring episode, Dr. Nancy Chedid—surgeon, educator, writer, musician, and cultural bridge—shares the extraordinary journey that shaped her life across the United States and Lebanon. From training at Yale, Johns Hopkins, NYU, and Harvard to rebuilding a life in Beirut after loss, Dr. Chedid reflects on identity, purpose, and the power of weaving medicine with the humanities. She discusses her memoir Snow on the Barbecue, her transformative years at LAU, the creation of humanities-in-medicine programs, and the profound impact of mentorship and community. We explore themes of home, displacement, grief, belonging, and reinvention. This episode is a tribute to the resilience of the human spirit and to the many ways one can build a meaningful life across continents.  #LebanesePhysiciansPodcast #NancyChedid #HumanitiesInMedicine #MedicineAndHumanities #MedicalEducation #PhysicianStories #WomenInMedicine #LebaneseDiaspora #ArabAmericanVoices #Lebanon #Beirut #DiasporaStories #Memoir #LifeTransitions #Resilience #Healing #HomeAndBelonging #IdentityAndCulture #StorytellingInMedicine #MentorshipMatters #AcademicMedicine #ArtsInMedicine #CreativeWritingInMedicine #GlobalMedicine #CrossCulturalJourneys #Reinvention #GriefAndHealing #BeirutPortExplosion #SnowOnTheBarbecue #LebaneseWriters #ArabDiaspora Episode also on YouTube    

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss the positive side effect of the shingles vaccine on dementia outcomes and how one dose of the HPV vaccine is non-inferior to two doses, but are dismayed about the FDA's secrecy around the inflammatory statement that the COVID-19 vaccine is linked to the death of 10 children. Dr. Griffin then deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, effectiveness of maternal administration of the RVS vaccine or the COVID vaccine for neonates, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, how celiac plexus blocks improves gastrointestinal long COVID symptoms, brain alterations and neurodegenerative processes in long COVID cognitive impairment and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode The effect of shingles vaccination at different stages of the dementia disease course (Cell) FDA links 10 children's deaths to COVID-19 vaccines. Doctors want proof (ABC News) Subject: Deaths in children due to COVID-19 vaccines and CBER's path forward Dear Team CBER,(Washington Post) Noninferiority of One HPV Vaccine Dose to Two Doses(NEJM) Marburg Outbreak in Ethiopia: Current Situation (CDC: Marburg Virus Disease) Washington state resident believed to be the first to die from a rare strain of bird flu (AP News) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Types of Influenza Viruses (CDC: Influenza (flu)) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season(FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Maternal and Neonatal Outcomes After Respiratory Syncytial Virus Prefusion F Protein Vaccination During Pregnancy (Obstetrics & Gynecology) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Effectiveness of COVID-19 vaccines against post-COVID-19 condition/long COVID: systematic review and meta-analysis (CMI: Clinical Microbiology and Infection) SARS-CoV-2Infection Versus Vaccination During Pregnancy: Implications for Placental Antibody Transfer (The Pediatric Infectious Disease Journal) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Case Report: Celiac plexus block improves gastrointestinal Long COVID symptoms (Frontiers Neuroscience) Distinct brain alterations and neurodegenerative processes in cognitive impairment associated with post-acute sequelae of COVID-19 (Nature Communications) Reaching out to US house representative Letters read on TWiV 1276 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

durée : 00:16:59 - L'Invité(e) des Matins - par : Guillaume Erner, Yoann Duval - 2026 sera-t-elle l'année des empires ? Et si la question était plutôt : quelles formes prendront les empires en 2026 ? - réalisation : Félicie Faugère - invités : Henry Farrell professeur de relations internationales à l'université Johns Hopkins aux Etats-Unis; Kim Ghattas journaliste libano-néerlandaise. Collaboratrice du magazine The Atlantic et éditrice au Financial Times

00:10:21 — Trump Declares Biden's Autopen Orders Invalid Knight breaks down Trump's claim that all autopen-signed Biden documents are void, warning this could unleash unprecedented legal and political chaos. 00:13:40 — Trump Will Never Go After Fauci Knight argues Trump cannot revoke Fauci-related decisions because he still embraces Operation Warp Speed and refuses to acknowledge vaccine harm. 00:15:14 — Rare-Earth Crisis Caused by U.S. Policy Failures Knight details how America lost control of rare-earth production due to political corruption, EPA restrictions, and China's strategic long-term planning. 00:37:44 — AEI & Johns Hopkins Exposed for Designing Lockdowns Knight reacts to evidence that AEI and Johns Hopkins crafted the original U.S. lockdown strategy — revealing the establishment origins of the Covid regime. 00:44:55 — Autopsies Show Vaccine Injury Across Multiple Organs Knight reviews new pathology data demonstrating widespread organ damage linked to mRNA vaccines, challenging official narratives on vaccine safety. 00:47:19 — Global Spike in Kidney Failure After Vaccination Knight highlights dramatic rises in fatal renal injury across multiple countries, calling it one of the clearest indicators of vaccine-associated harm. 00:58:24 — MIT Predicts AI Will Erase 20 Million U.S. Jobs Knight explains MIT's model showing that AI could immediately wipe out one-eighth of American employment, triggering a corporate-engineered depression. 00:59:10 — AI Job Loss Becomes a Trillion-Dollar Wealth Transfer Knight argues AI isn't replacing workers for efficiency but to funnel $1.2 trillion in wages upward to corporate elites. 01:06:38 — Anthropic's “AI Soul” Document Reveals Transhumanist Agenda Knight exposes how AI developers deliberately push the idea of machine consciousness to manipulate public perception and normalize post-human ideology. 01:14:37 — Businesses Abandon AI After Failure to Deliver Results Knight shows Census Bureau data revealing steep declines in AI adoption, demonstrating widespread disillusionment after years of hype. 02:03:03 — Billionaire Silver Purchase Exposes Fragile Supply Chain Tony reveals a single $500M silver order stressed dealers nationwide, proving how thin and unstable the physical silver market has become. 02:08:56 — National Silver Supply Crisis: Mining Cannot Meet Demand Knight and Tony explain how global silver production is collapsing even as industrial and governmental demand soars, creating unstoppable upward pressure on prices. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

00:10:21 — Trump Declares Biden's Autopen Orders Invalid Knight breaks down Trump's claim that all autopen-signed Biden documents are void, warning this could unleash unprecedented legal and political chaos. 00:13:40 — Trump Will Never Go After Fauci Knight argues Trump cannot revoke Fauci-related decisions because he still embraces Operation Warp Speed and refuses to acknowledge vaccine harm. 00:15:14 — Rare-Earth Crisis Caused by U.S. Policy Failures Knight details how America lost control of rare-earth production due to political corruption, EPA restrictions, and China's strategic long-term planning. 00:37:44 — AEI & Johns Hopkins Exposed for Designing Lockdowns Knight reacts to evidence that AEI and Johns Hopkins crafted the original U.S. lockdown strategy — revealing the establishment origins of the Covid regime. 00:44:55 — Autopsies Show Vaccine Injury Across Multiple Organs Knight reviews new pathology data demonstrating widespread organ damage linked to mRNA vaccines, challenging official narratives on vaccine safety. 00:47:19 — Global Spike in Kidney Failure After Vaccination Knight highlights dramatic rises in fatal renal injury across multiple countries, calling it one of the clearest indicators of vaccine-associated harm. 00:58:24 — MIT Predicts AI Will Erase 20 Million U.S. Jobs Knight explains MIT's model showing that AI could immediately wipe out one-eighth of American employment, triggering a corporate-engineered depression. 00:59:10 — AI Job Loss Becomes a Trillion-Dollar Wealth Transfer Knight argues AI isn't replacing workers for efficiency but to funnel $1.2 trillion in wages upward to corporate elites. 01:06:38 — Anthropic's “AI Soul” Document Reveals Transhumanist Agenda Knight exposes how AI developers deliberately push the idea of machine consciousness to manipulate public perception and normalize post-human ideology. 01:14:37 — Businesses Abandon AI After Failure to Deliver Results Knight shows Census Bureau data revealing steep declines in AI adoption, demonstrating widespread disillusionment after years of hype. 02:03:03 — Billionaire Silver Purchase Exposes Fragile Supply Chain Tony reveals a single $500M silver order stressed dealers nationwide, proving how thin and unstable the physical silver market has become. 02:08:56 — National Silver Supply Crisis: Mining Cannot Meet Demand Knight and Tony explain how global silver production is collapsing even as industrial and governmental demand soars, creating unstoppable upward pressure on prices. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

An Explosive Debate on Trump's Brain. Dr. John Gartner, former Johns Hopkins psychiatry faculty member and a vocal critic of Donald Trump, joins Live From the Table. We challenge Gartner directly on his claims that Donald Trump is exhibiting malignant narcissism, psychopathy, and accelerating dementia. The debate spans science, politics, ethics, medical bias, and the media's treatment of both Trump and Biden. This episode includes extended transcript-verified clips, counter-arguments, and some of the most heated exchanges we've aired. Chapters below. Chapters 00:00 – Intro: Who is Dr. John Gartner? 01:00 – Goldwater Rule & Diagnosing Public Figures 03:20 – Trump, Narcissism & Malignant Personality Disorders 07:00 – Is Trump a Psychopath? Criminality, Lying & Abuse 11:20 – Noam Pushes Back: What Counts as Evidence? 14:15 – The Dementia Question: Language, Gait & Decline 16:55 – “He's Not the Same Man”: Claims From Former Officials 18:45 – Noam's Counterargument: Bolton, Kelly, McMaster, Woodward 22:30 – Cognitive Decline vs. Strategy: What's Real? 26:05 – Trump's Speeches Examined: Word Salad or Something Else? 29:30 – The “Skedaddle” Story & Loose Associations 33:00 – Kamala Harris, Biden & Claims of Asymmetrical Scrutiny 37:10 – Debate Clips: Biden Then vs. Now, Trump Then vs. Now 41:50 – Variability & Sundowning: How Dementia Presents 45:00 – Trump's Stamina vs. Trump's Disorganization 48:20 – Is This Cognitive Decline or Just Aging? 52:00 – Impulsivity, National Security & Dangerous Decision-Making 56:10 – The Hakeem Jeffries “Very Nice Man” Story 59:00 – Biden Wandering Clips & Why the Medical Community Stayed Silent 1:02:00 – Is Medical Bias Real? Noam Pushes Gartner 1:04:00 – Would Trump's Inner Circle Have Noticed Decline? 1:07:00 – Narcissism, Children & Why His Family Keeps Distance 1:10:00 – “Do You Feel Sympathy for Him?” 1:14:00 – Closing Thoughts & Invitation to Visit the Cellar

 If you're a scientist, and you apply for federal research funding, you'll ask for a specific dollar amount. Let's say you're asking for a million-dollar grant. Your grant covers the direct costs, things like the salaries of the researchers that you're paying. If you get that grant, your university might get an extra $500,000. That money is called “indirect costs,” but think of it as overhead: that money goes to lab space, to shared equipment, and so on.This is the system we've used to fund American research infrastructure for more than 60 years. But earlier this year, the Trump administration proposed capping these payments at just 15% of direct costs, way lower than current indirect cost rates. There are legal questions about whether the admin can do that. But if it does, it would force universities to fundamentally rethink how they do science.The indirect costs system is pretty opaque from the outside. Is the admin right to try and slash these indirect costs? Where does all that money go? And if we want to change how we fund research overhead, what are the alternatives? How do you design a research system to incentivize the research you actually wanna see in the world?I'm joined today by Pierre Azoulay from MIT Sloan and Dan Gross from Duke's Fuqua School of Business. Together with Bhaven Sampat at Johns Hopkins, they conducted the first comprehensive empirical study of how indirect costs actually work. Earlier this year, I worked with them to write up that study as a more accessible policy brief for IFP. They've assembled data on over 350 research institutions, and they found some striking results. While negotiated rates often exceed 50-60%, universities actually receive much less, due to built-in caps and exclusions.Moreover, the institutions that would be hit hardest by proposed cuts are those whose research most often leads to new drugs and commercial breakthroughs.Thanks to Katerina Barton, Harry Fletcher-Wood, and Inder Lohla for their help with this episode, and to Beez for her help on the charts.Let's say I'm a researcher at a university and I apply for a federal grant. I'm looking at cancer cells in mice. It will cost me $1 million to do that research — to pay grad students, to buy mice and test tubes. I apply for a grant from the National Institutes of Health, or NIH. Where do indirect costs come in?Dan Gross: Research generally incurs two categories of costs, much as business operations do.* Direct or variable costs are typically project-specific; they include salaries and consumable supplies.* Indirect or fixed costs are not as easily assigned to any particular project. [They include] things like lab space, data and computing resources, biosecurity, keeping the lights on and the buildings cooled and heated — even complying with the regulatory requirements the federal government imposes on researchers. They are the overhead costs of doing research.Pierre Azoulay: You will use those grad students, mice, and test tubes, the direct costs. But you're also using the lab space. You may be using a shared facility where the mice are kept and fed. Pieces of large equipment are shared by many other people to conduct experiments. So those are fixed costs from the standpoint of your research project.Dan: Indirect Cost Recovery (ICR) is how the federal government has been paying for the fixed cost of research for the past 60 years. This has been done by paying universities institution-specific fixed percentages on top of the direct cost of the research. That's the indirect cost rate. That rate is negotiated by institutions, typically every two to four years, supported by several hundred pages of documentation around its incurred costs over the recent funding cycle.The idea is to compensate federally funded researchers for the investments, infrastructure, and overhead expenses related to the research they perform for the government. Without that funding, universities would have to pay those costs out of pocket and, frankly, many would not be interested or able to do the science the government is funding them to do.Imagine I'm doing my mouse cancer science at MIT, Pierre's parent institution. Some time in the last four years, MIT had this negotiation with the National Institutes of Health to figure out what the MIT reimbursable rate is. But as a researcher, I don't have to worry about what indirect costs are reimbursable. I'm all mouse research, all day.Dan: These rates are as much of a mystery to the researchers as it is to the public. When I was junior faculty, I applied for an external grant from the National Science Foundation (NSF) — you can look up awards folks have won in the award search portal. It doesn't break down indirect and direct cost shares of each grant. You see the total and say, “Wow, this person got $300,000.” Then you go to write your own grant and realize you can only budget about 60% of what you thought, because the rest goes to overhead. It comes as a bit of a shock the first time you apply for grant funding.What goes into the overhead rates? Most researchers and institutions don't have clear visibility into that. The process is so complicated that it's hard even for those who are experts to keep track of all the pieces.Pierre: As an individual researcher applying for a project, you think about the direct costs of your research projects. You're not thinking about the indirect rate. When the research administration of your institution sends the application, it's going to apply the right rates.So I've got this $1 million experiment I want to run on mouse cancer. If I get the grant, the total is $1.5 million. The university takes that .5 million for the indirect costs: the building, the massive microscope we bought last year, and a tiny bit for the janitor. Then I get my $1 million. Is that right?Dan: Duke University has a 61% indirect cost rate. If I propose a grant to the NSF for $100,000 of direct costs — it might be for data, OpenAI API credits, research staff salaries — I would need to budget an extra $61,000 on top for ICR, bringing the total grant to $161,000.My impression is that most federal support for research happens through project-specific grants. It's not these massive institutional block grants. Is that right?Pierre: By and large, there aren't infrastructure grants in the science funding system. There are other things, such as center grants that fund groups of investigators. Sometimes those can get pretty large — the NIH grant for a major cancer center like Dana-Farber could be tens of millions of dollars per year.Dan: In the past, US science funding agencies did provide more funding for infrastructure and the instrumentation that you need to perform research through block grants. In the 1960s, the NSF and the Department of Defense were kicking up major programs to establish new data collection efforts — observatories, radio astronomy, or the Deep Sea Drilling project the NSF ran, collecting core samples from the ocean floor around the world. The Defense Advanced Research Projects Agency (DARPA) — back then the Advanced Research Projects Agency (ARPA) — was investing in nuclear test detection to monitor adherence to nuclear test ban treaties. Some of these were satellite observation methods for atmospheric testing. Some were seismic measurement methods for underground testing. ARPA supported the installation of a network of seismic monitors around the world. Those monitors are responsible for validating tectonic plate theory. Over the next decade, their readings mapped the tectonic plates of the earth. That large-scale investment in research infrastructure is not as common in the US research policy enterprise today.That's fascinating. I learned last year how modern that validation of tectonic plate theory was. Until well into my grandparents' lifetime, we didn't know if tectonic plates existed.Dan: Santi, when were you born?1997.Dan: So I'm a good decade older than you — I was born in 1985. When we were learning tectonic plate theory in the 1990s, it seemed like something everybody had always known. It turns out that it had only been known for maybe 25 years.So there's this idea of federal funding for science as these massive pieces of infrastructure, like the Hubble Telescope. But although projects like that do happen, the median dollar the Feds spend on science today is for an individual grant, not installing seismic monitors all over the globe.Dan: You applied for a grant to fund a specific project, whose contours you've outlined in advance, and we provided the funding to execute that project.Pierre: You want to do some observations at the observatory in Chile, and you are going to need to buy a plane ticket — not first class, not business class, very much economy.Let's move to current events. In February of this year, the NIH announced it was capping indirect cost reimbursement at 15% on all grants.What's the administration's argument here?Pierre: The argument is there are cases where foundations only charge 15% overhead rate on grants — and universities acquiesce to such low rates — and the federal government is entitled to some sort of “most-favored nation” clause where no one pays less in overhead than they pay. That's the argument in this half-a-page notice. It's not much more elaborate than that.The idea is, the Gates Foundation says, “We will give you a grant to do health research and we're only going to pay 15% indirect costs.” Some universities say, “Thank you. We'll do that.” So clearly the universities don't need the extra indirect cost reimbursement?Pierre: I think so.Dan: Whether you can extrapolate from that to federal research funding is a different question, let alone if federal research was funding less research and including even less overhead. Would foundations make up some of the difference, or even continue funding as much research, if the resources provided by the federal government were lower? Those are open questions. Foundations complement federal funding, as opposed to substitute for it, and may be less interested in funding research if it's less productive.What are some reasons that argument might be misguided?Pierre: First, universities don't always say, “Yes” [to a researcher wishing to accept a grant]. At MIT, getting a grant means getting special authorization from the provost. That special authorization is not always forthcoming. The provost has a special fund, presumably funded out of the endowment, that under certain conditions they will dip into to make up for the missing overhead.So you've got some research that, for whatever reason, the federal government won't fund, and the Gates Foundation is only willing to fund it at this low rate, and the university has budgeted a little bit extra for those grants that it still wants.Pierre: That's my understanding. I know that if you're going to get a grant, you're going to have to sit in many meetings and cajole any number of administrators, and you don't always get your way.Second, it's not an apples-to-apples comparison [between federal and foundation grants] because there are ways to budget an item as a direct cost in a foundation grant that the government would consider an indirect cost. So you might budget some fractional access to a facility…Like the mouse microscope I have to use?Pierre: Yes, or some sort of Cryo-EM machine. You end up getting more overhead through the back door.The more fundamental way in which that approach is misguided is that the government wants its infrastructure — that it has contributed to through [past] indirect costs — to be leveraged by other funders. It's already there, it's been paid for, it's sitting idle, and we can get more bang for our buck if we get those additional funders to piggyback on that investment.Dan: That [other funders] might not be interested in funding otherwise.Why wouldn't they be interested in funding it otherwise? What shouldn't the federal government say, “We're going to pay less. If it's important research, somebody else will pay for it.”Dan: We're talking about an economies-of-scale problem. These are fixed costs. The more they're utilized, the more the costs get spread over individual research projects.For the past several decades, the federal government has funded an order of magnitude more university research than private firms or foundations. If you look at NSF survey data, 55% of university R&D is federally funded; 6% is funded by foundations. That is an order of magnitude difference. The federal government has the scale to support and extract value for whatever its goals are for American science.We haven't even started to get into the administrative costs of research. That is part of the public and political discomfort with indirect-cost recovery. The idea that this is money that's going to fund university bloat.I should lay my cards on the table here for readers. There are a ton of problems with the American scientific enterprise as it currently exists. But when you look at studies from a wide range of folks, it's obvious that R&D in American universities is hugely valuable. Federal R&D dollars more than pay for themselves. I want to leave room for all critiques of the scientific ecosystem, of the universities, of individual research ideas. But at this 30,000-foot level, federal R&D dollars are well spent.Dan: The evidence may suggest that, but that's not where the political and public dialogue around science policy is. Again, I'm going to bring in a long arc here. In the 1950s and 1960s, it was, “We're in a race with the Soviet Union. If we want to win this race, we're going to have to take some risky bets.” And the US did. It was more flexible with its investments in university and industrial science, especially related to defense aims. But over time, with the waning of these political pressures and with new budgetary pressures, the tenor shifted from, “Let's take chances” to “Let's make science and other parts of government more accountable.” The undercurrent of Indirect Cost Recovery policy debates has more of this accountability framing.This comes up in this comparison to foundation rates: “Is the government overpaying?” Clearly universities are willing to accept less from foundations. It comes up in this perception that ICR is funding administrative growth that may not be productive or socially efficient. Accountability seems to be a priority in the current day.Where are we right now [August 2025] on that 15% cap on indirect costs?Dan: Recent changes first kicked off on February 7th, when NIH posted its supplemental guidance, that introduced a policy that the direct cost rates that it paid on its grants would be 15% to institutions of higher education. That policy was then adopted by the NSF, the DOD, and the Department of Energy. All of these have gotten held up in court by litigation from universities. Things are stuck in legal limbo. Congress has presented its point of view that, “At least for now, I'd like to keep things as they are.” But this has been an object of controversy long before the current administration even took office in January. I don't think it's going away.Pierre: If I had to guess, the proposal as it first took shape is not what is going to end up being adopted. But the idea that overhead rates are an object of controversy — are too high, and need to be reformed — is going to stay relevant.Dan: Partly that's because it's a complicated issue. Partly there's not a real benchmark of what an appropriate Indirect Cost Recovery policy should be. Any way you try to fund the cost of research, you're going to run into trade-offs. Those are complicated.ICR does draw criticism. People think it's bloated or lacks transparency. We would agree some of these critiques are well-founded. Yet it's also important to remember that ICR pays for facilities and administration. It doesn't just fund administrative costs, which is what people usually associate it with. The share of ICR that goes to administrative costs is legally capped at 26% of direct costs. That cap has been in place since 1991. Many universities have been at that cap for many years — you can see this in public records. So the idea that indirect costs are going up over time, and that that's because of bloat at US universities, has to be incorrect, because the administrative rate has been capped for three decades.Many of those costs are incurred in service of complying with regulations that govern research, including the cost of administering ICR to begin with. Compiling great proposals every two to four years and a new round of negotiations — all of that takes resources. Those are among the things that indirect cost funding reimburses.Even then, universities appear to under-recover their true indirect costs of federally-sponsored research. We have examples from specific universities which have reported detailed numbers. That under-recovery means less incentive to invest in infrastructure, less capacity for innovation, fewer clinical trials. So there's a case to be made that indirect cost funding is too low.Pierre: The bottom line is we don't know if there is under- or over-recovery of indirect costs. There's an incentive for university administrators to claim there's under-recovery. So I take that with a huge grain of salt.Dan: It's ambiguous what a best policy would look like, but this is all to say that, first, public understanding of this complex issue is sometimes a bit murky. Second, a path forward has to embrace the trade-offs that any particular approach to ICR presents.From reading your paper, I got a much better sense that a ton of the administrative bloat of the modern university is responding to federal regulations on research. The average researcher reports spending almost half of their time on paperwork. Some of that is a consequence of the research or grant process; some is regulatory compliance.The other thing, which I want to hear more on, is that research tools seem to be becoming more expensive and complex. So the microscope I'm using today is an order of magnitude more expensive than the microscope I was using in 1950. And you've got to recoup those costs somehow.Pierre: Everything costs more than it used to. Research is subject to Baumol's cost disease. There are areas where there's been productivity gains — software has had an impact.The stakes are high because, if we get this wrong, we're telling researchers that they should bias the type of research they're going to pursue and training that they're going to undergo, with an eye to what is cheaper. If we reduce the overhead rate, we should expect research that has less fixed cost and more variable costs to gain in favor — and research that is more scale-intensive to lose favor. There's no reason for a benevolent social planner to find that a good development. The government should be neutral with respect to the cost structure of research activities. We don't know in advance what's going to be more productive.Wouldn't a critic respond, “We're going to fund a little bit of indirect costs, but we're not going to subsidize stuff that takes huge amounts of overhead. If universities want to build that fancy new telescope because it's valuable, they'll do it.” Why is that wrong when it comes to science funding?Pierre: There's a grain of truth to it.Dan: With what resources though? Who's incentivized to invest in this infrastructure? There's not a paid market for science. Universities can generate some licensing fees from patents that result from science. But those are meager revenue streams, realistically. There are reasons to believe that commercial firms are under-incentivized to invest in basic scientific research. Prior to 1940, the scientific enterprise was dramatically smaller because there wasn't funding the way that there is today. The exigencies of war drew the federal government into funding research in order to win. Then it was productive enough that folks decided we should keep doing it. History and economic logic tells us that you're not going to see as much science — especially in these fixed-cost heavy endeavors — when those resources aren't provided by the public.Pierre: My one possible answer to the question is, “The endowment is going to pay for it.” MIT has an endowment, but many other universities do not. What does that mean for them? The administration also wants to tax the heck out of the endowment.This is a good opportunity to look at the empirical work you guys did in this great paper. As far as I can tell, this was one of the first real looks at what indirect costs rates look like in real life. What did you guys find?Dan: Two decades ago, Pierre and Bhaven began collecting information on universities' historical indirect cost rates. This is a resource that was quietly sitting on the shelf waiting for its day. That day came this past February. Bhaven and Pierre collected information on negotiated ICR rates for the past 60 years. During this project, we also collected the most recent versions of those agreements from university websites to bring the numbers up to the current day.We pulled together data for around 350 universities and other research institutions. Together, they account for around 85% of all NIH research funding over the last 20 years.We looked at their:* Negotiated indirect cost rates, from institutional indirect cost agreements with the government, and their;* Effective rates [how much they actually get when you look at grant payments], using NIH grant funding data.Negotiated cost rates have gone up. That has led to concerns that the overhead cost of research is going up — these claims that it's funding administrative bloat. But our most important finding is that there's a large gap between the sticker rates — the negotiated ICR rates that are visible to the public, and get floated on Twitter as examples of university exorbitance — and the rates that universities are paid in practice, at least on NIH grants; we think it's likely the case for NSF and other agency grants too.An institution's effective ICR funding rates are much, much lower than their negotiated rates and they haven't changed much for 40 years. If you look at NIH's annual budget, the share of grant funding that goes to indirect costs has been roughly constant at 27-28% for a long time. That implies an effective rate of around 40% over direct costs. Even though many institutions have negotiated rates of 50-70%, they usually receive 30-50%.The difference between those negotiated rates and the effective rates seems to be due to limits and exceptions built into NIH grant rules. Those rules exclude some grants, such as training grants, from full indirect cost funding. They also exclude some direct costs from the figure used to calculate ICR rates. The implication is that institutions receive ICR payments based on a smaller portion of their incurred direct costs than typically assumed. As the negotiated direct cost falls, you see a university being paid a higher indirect cost rate off a smaller — modified — direct cost base, to recover the same amount of overhead.Is it that the federal government is saying for more parts of the grant, “We're not going to reimburse that as an indirect cost.”?Dan: This is where we shift a little bit from assessment to speculation. What's excluded from total direct costs? One thing is researcher salaries above a certain level.What is that level? Can you give me a dollar amount?Dan: It's a $225,700 annual salary. There aren't enough people being paid that on these grants for that to explain the difference, especially when you consider that research salaries are being paid to postdocs and grad students.You're looking around the scientists in your institution and thinking, “That's not where the money is”?Dan: It's not, even if you consider Principal Investigators. If you consider postdocs and grad students, it certainly isn't.Dan: My best hunch is that research projects have become more capital-intensive, and only a certain level of expenditure on equipment can be included in the modified total direct cost base. I don't have smoking gun evidence, it's my intuition.In the paper, there's this fascinating chart where you show the institutions that would get hit hardest by a 15% cap tend to be those that do the most valuable medical research. Explain that on this framework. Is it that doing high-quality medical research is capital-intensive?Pierre: We look at all the private-sector patents that build on NIH research. The more a university stands to lose under the administration policy, the more it has contributed over the past 25 years — in research the private sector found relevant in terms of pharmaceutical patents.This is counterintuitive if your whole model of funding for science is, “Let's cut subsidies for the stuff the private sector doesn't care about — all this big equipment.” When you cut those subsidies, what suffers most is the stuff that the private sector likes.Pierre: To me it makes perfect sense. This is the stuff that the private sector would not be willing to invest in on its own. But that research, having come into being, is now a very valuable input into activities that profit-minded investors find interesting and worth taking a risk on.This is the argument for the government to fund basic research?Pierre: That argument has been made at the macro-level forever, but the bibliometric revolution of the past 15 years allows you to look at this at the nano-level. Recently I've been able to look at the history of Ozempic. The main patent cites zero publicly-funded research, but it cites a bunch of patents, including patents taken up by academics. Those cite the foundational research performed by Joel Habener and his team at Massachusetts General Hospital in the early 1980s that elucidated the role of GLP-1 as a potential target. This grant was first awarded to Habener in 1979, was renewed every four or five years, and finally died in 2008, when he moved on to other things. Those chains are complex, but we can now validate the macro picture at this more granular level.Dan: I do want to add one qualification which also suggests some directions for the future. There are things we still can't see — despite Pierre's zeal. Our projections of the consequence of a 15% rate cap are still pretty coarse. We don't know what research might not take place. We don't know what indirect cost categories are exposed, or how universities would reallocate. All those things are going to be difficult to project without a proper experiment.One thing that I would've loved to have more visibility into is, “What is the structure of indirect costs at universities across the country? What share of paid indirect costs are going to administrative expenses? What direct cost categories are being excluded?” We would need a more transparency into the system to know the answers.Does that information have to be proprietary? It's part of negotiations with the federal government about how much the taxpayer will pay for overhead on these grants. Which piece is so special that it can't be shared?Pierre: You are talking to the wrong people here because we're meta-scientists, so our answer is none of it should be private.Dan: But now you have to ask the university lawyers.What would the case from the universities be? “We can't tell the public what we spend subsidy on”?Pierre: My sense is that there are institutions of academia that strike most lay people as completely bizarre.Hard to explain without context?Pierre: People haven't thought about it. They will find it so bizarre that they will typically jump from the odd aspect to, “That must be corruption.” University administrators are hugely attuned to that. So the natural defensive approach is to shroud it in secrecy. This way we don't see how the sausage is made.Dan: Transparency can be a blessing and a curse. More information supports more considered decision-making. It also opens the door to misrepresentation by critics who have their own agendas. Pierre's right: there are some practices that to the public might look unusual — or might be familiar, but one might say, “How is that useful expense?” Even a simple thing like having an administrator who manages a faculty's calendar might seem excessive. Many people manage their own calendars. At the same time, when you think about how someone's time is best used, given their expertise, and heavy investment in specialized human capital, are emails, calendaring, and note-taking the right things for scientists [to be doing]? Scientists spend a large chunk of their time now administering grants. Does it make sense to outsource that and preserve the scientist's time for more science?When you put forward data that shows some share of federal research funding is going to fund administrative costs, at first glance it might look wasteful, yet it might still be productive. But I would be able to make a more considered judgment on a path forward if I had access to more facts, including what indirect costs look like under the hood.One last question: in a world where you guys have the ear of the Senate, political leadership at the NIH, and maybe the universities, what would you be pushing for on indirect costs?Pierre: I've come to think that this indirect cost rate is a second-best institution: terrible and yet superior to many of the alternatives. My favorite alternative would be one where there would be a flat rate applied to direct costs. That would be the average effective rate currently observed — on the order of 40%.You're swapping out this complicated system to — in the end — reimburse universities the same 40%.Pierre: We know there are fixed costs. Those fixed costs need to be paid. We could have an elaborate bureaucratic apparatus to try to get it exactly right, but it's mission impossible. So why don't we give up on that and set a rate that's unlikely to lead to large errors in under- or over-recovery. I'm not particularly attached to 40%. But the 15% that was contemplated seems absurdly low.Dan: In the work we've done, we do lay out different approaches. The 15% rate wouldn't fully cut out the negotiation process: to receive that, you have to document your overhead costs and demonstrate that they reached that level. In any case, it's simplifying. It forces more cost-sharing and maybe more judicious investments by universities. But it's also so low that it's likely to make a significant amount of high-value, life-improving research economically unattractive.The current system is complicated and burdensome. It might encourage investment in less productive things, particularly because universities can get it paid back through future ICR. At the same time, it provides pretty good incentives to take on expensive, high-value research on behalf of the public.I would land on one of two alternatives. One of those is close to what Pierre said, with fixed rates, but varied by institution types: one for universities, one for medical schools, one for independent research institutions — because we do see some variation in their cost structures. We might set those rates around their historical average effective rates, since those haven't changed for quite a long time. If you set different rates for different categories of institution, the more finely you slice the pie, the closer you end up to the current system. So that's why I said maybe, at a very high level, four categories.The other I could imagine is to shift more of these costs “above the line” — to adapt the system to enable more of these indirect costs to be budgeted as direct costs in grants. This isn't always easy, but presumably some things we currently call indirect costs could be accounted for in a direct cost manner. Foundations do it a bit more than the federal government does, so that could be another path forward.There's no silver bullet. Our goal was to try to bring some understanding to this long-running policy debate over how to fund the indirect cost of research and what appropriate rates should be. It's been a recurring question for several decades and now is in the hot seat again. Hopefully through this work, we've been able to help push that dialogue along. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.statecraft.pub

The Rich Zeoli Show- Hour 4: 6:00pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. Trump described the policy shift as a win for consumers—as the previous efficiency standards led to higher prices on new vehicles. 6:30pm-While speaking with New York Post reporter Miranda Devine, FDA Director and Johns Hopkins surgeon Dr. Marty Makary documented the ways former Director of the National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci was involved in a massive attempt to suppress the truth about Covid-19's origins. 6:40pm- A report from Ernesto Londono of The New York Times documents rampant fraud plaguing Minnesota—dozens of people have been charged with stealing more than $1 billion in taxpayer money from programs meant to feed hungry children and provide therapy for autistic children. Critics of Governor Tim Walz say his administration allowed the fraud to persist “partly because state officials were fearful of alienating the Somali community” who were largely responsible for the scams.

The Rich Zeoli Show- Full Show (12/03/2025): 3:05pm- A report from Ernesto Londono of The New York Times documents rampant fraud plaguing Minnesota—dozens of people have been charged with stealing more than $1 billion in taxpayer money from programs meant to feed hungry children and provide therapy for autistic children. Critics of Governor Tim Walz say his administration allowed the fraud to persist “partly because state officials were fearful of alienating the Somali community” who were largely responsible for the scams. 3:10pm- While speaking with the press on Tuesday, President Donald Trump called for a reduction of migrants from third world countries who are openly unwilling to assimilate to American culture. 3:20pm- Philadelphia Highway Patrol Officer Andy Chan has died six years after he was struck by a vehicle while on duty. Rich notes that Officer Chan was a friend of the show. Next Friday the show will be broadcasting from the 6th Annual Andy Chan Holiday Block Party. 3:30pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. 4:05pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. Trump described the policy shift as a win for consumers—as the previous efficiency standards led to higher prices on new vehicles. 4:40pm- Carrie Severino—President of the Judicial Crisis Network (JCN) & Co-Author of the book, “Justice on Trial: The Kavanaugh Confirmation and the Future of the Supreme Court.”—joins The Rich Zeoli Show. On Tuesday, the U.S. Supreme Court heard oral argument in First Choice Women's Resource Centers v. Platkin. The case asks whether a federal court can hear First Choice's First Amendment challenge to a New Jersey investigatory subpoena when no state court has yet ordered the group to comply. While being questioned by Justice Clarence Thomas, NJ Attorney General Sundeep Iyer conceded that NJ hasn't received any public complaints to justify its subpoena against the pro-life health center. 5:05pm- A Washington Post report states that Department of War Secretary Pete Hegseth authorized a series of deadly strikes on a drug trafficking boat in the Caribbean, ordering military officials to “kill everybody.” The directive, according to the report, led to a second strike killing several crew members that survived the initial assault on the vessel. The New York Times, as well as the White House, dispute that Hegseth explicitly authorized the second strike or ordered to eliminate survivors. The NYT also reports that the “U.S. military intercepted radio communications from one of the survivors to what [officials] said were narco-traffickers.” 5:30pm- Following the Eagles loss to the Bears on Friday, Offensive Coordinator Kevin Patullo had his house egged. Does Justin have an alibi? Plus, a drunk racoon ransacked a convenience store! And “Be Nice to Matt Week” continues…sort of… 6:00pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. Trump described the policy shift as a win for consumers—as the previous efficiency standards led to higher prices on new vehicles. 6:30pm-While speaking with New York Post reporter Miranda Devine, FDA Director and Johns Hopkins surgeon Dr. Marty Makary documented the ways former Director of the National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci was involved in a ma ...

Dr. Ryan Vandrey is a professor of Psychiatry and Behavioral Sciences at Johns Hopkins. Dr. Johannes Thrul is an Associate Professor at Johns Hopkins. They both work for the Cannabis Health & Research Initiative, which is a collaboration between two organizations with years of experience in medicinal cannabis research: Johns Hopkins University and Realm of Caring. Simply put, CHRI is a platform of data collection and dissemination focused on the health outcomes of medicinal cannabis at the patient level, and they have created a number of valuable resources to help cannabis medicine researchers, including: A data repository that contains de-identified data collected through CHRI Research Library that contains more than 3000 published scientific articles related to the health effects of cannabis A set of validated questionnares that clinicians can use when speaking to patients about cannabis – and more The CHRI is also currently recruiting participants for their National Cannabis Study, which is a collection of firsthand experiences with medicinal cannabis among individuals with various health conditions. Specifically, they are looking for participants who plan to use cannabis but have not yet started cannabis use. So if that's you or someone you know, we highly suggest you consider participating in the study because the research has the potential to impact best practices in healthcare and the cannabis industry. During our conversation, Ryan and Johannes shared more details about the CHRI and the National Cannabis Study, and I think you will agree that their mission aligns perfectly with the CannMed Community. Thanks to This Episode’s Sponsor: Realm of Caring Founded in 2013, Realm of Caring (RoC) serves anyone in need of more information about cannabinoid therapies. Through revolutionary CBD and Cannabis research, innovative education, and life-changing grants, RoC seeks to facilitate and encourage the mainstream acceptance of transformative, plant powered therapies to benefit individuals and families and serve healthcare providers as well as the hemp and cannabis industries. Learn more at realmofcaring.org Additional Resources Cannabis Health Research Initiative website – cannabisandhealth.org

Show notes: (0:00) Intro (1:17) Dr. Andrew Koutnik's background & obesity struggles (5:00) Lifestyle's surprising role in autoimmune disease risk (7:47) The rise of metabolic dysfunction in kids and adults (13:17) Key health markers to watch (18:55) Can a ketogenic diet reverse metabolic dysfunction? (30:04) 10-year ketogenic case study results (42:30) Advice for the "average" person looking to feel better (51:10) How to reduce carbs without giving up your favorite foods (57:50) Why short-term cravings can cost your long-term health (1:01:10) Why current diabetes guidelines may not reflect the latest science (1:08:36) Final thoughts and where to find Dr. Koutnik's resources (1:09:21) Outro Who is Dr. Andrew Koutnik?   Dr. Andrew Koutnik, PhD, is a biomedical researcher with expertise in metabolism, nutrition, and disease. He earned his PhD at Florida State University in Biomedical Sciences, studying how metabolism-based therapies like the ketogenic diet impact health and performance. He has worked with leading institutions, including NASA, Harvard, Johns Hopkins, and the Department of Defense, translating cutting-edge research into practical tools for improving metabolic health, managing chronic disease, and optimizing physical and cognitive performance.   As someone living with type 1 diabetes, Dr. Koutnik combines deep scientific knowledge with personal experience. He has published extensively on topics such as metabolic therapy, insulin resistance, and the ketogenic diet's role in chronic disease. He is also an advocate for evidence-based lifestyle interventions and works directly with elite athletes, military professionals, and everyday individuals to help them thrive through science-backed nutrition and lifestyle strategies.   Connect with Dr. Koutnik: Website: http://andrewkoutnik.com IG: https://www.instagram.com/andrewkoutnikphd/ YT: https://www.youtube.com/@AKoutnik     Links and Resources: Peak Performance Life Peak Performance on Facebook Peak Performance on Instagram

Send us a textRachael Wonderlin built a national dementia consulting firm from a Tumblr blog, three Johns Hopkins books, and a decade of hands-on work inside senior living communities. But the real story is what she learned along the way about boundaries, burnout, and trusting her intuition long before the data caught up.In this conversation, Rachael shares the full arc of building Dementia By Day from a one-woman hustle into a recurring revenue business that now operates like fractional operations for senior living companies. She talks about the early years when she said yes to everything, the moment she realized she needed a different model, and the systems she created to stop chasing one-off gigs.She also opens up about being pigeonholed as “just” a dementia expert, the tone deaf advice she received while pitching her fourth book, and the unregulated coaching industry that inspired her business memoir, I Can't Hustle Any Harder Than This.If you're building a business, struggling with boundaries, or fighting your way out of a niche that people keep trying to trap you in, this episode gives you the clarity you need to move forward with confidence.In this episode, Rachael shares: • How she turned a blog into a national consulting firm • The moment she learned to stop saying yes to everything • How she built recurring revenue and stopped chasing the next gig • The difference between coaching and consulting, and why clarity matters • Why the coaching industry can harm entrepreneurs who are just getting started • The story of the agent who told her to write a “funny dementia book” • How she is repositioning herself as a business leader, not only a dementia expert • The evolution of dementia care and why public awareness has changed • Why she refuses to use AI to create content • How her viral web comics reached hundreds of thousands of people • What hiring mistakes taught her about leadership and trust • The one lesson she wants every business owner to learn: if your gut says no, believe itKey quote: “If your gut reaction is ‘oh hell no,' that is the answer. Stop arguing with yourself. Say no and move on.”CONTACT INFORMATIONRachael Wonderlin Founder and CEO, Dementia By Day Website: dementiabyday.com LinkedIn: linkedin.com/in/rachaelwonderlin Instagram: @dementiabyday and @cant_hustleanyharder Substack: Can't Hustle Any Harder--- Subscribe and ReviewIf you loved this episode, drop us a review, share it with a badass woman in your life, and subscribe to Badass Women in Business wherever you get your podcasts. Stay badass. Stay bold. Build it your way. Keep up with more content from Aggie and Cristy here: Facebook: Empowered Women Leaders Instagram: @badass_women_in_business LinkedIn: ProveHer - Badass Women in Business Website: Badasswomeninbusinesspodcast.com Athena: athenaac.com

The Rich Zeoli Show- Hour 4: 6:00pm- A Washington Post report states that Department of War Secretary Pete Hegseth authorized a series of deadly strikes on a drug trafficking boat in the Caribbean, ordering military officials to “kill everybody.” The directive, according to the report, led to a second strike killing several crew members that survived the initial assault on the vessel. 6:20pm- Food and Drug Administration (FDA) Commissioner, and Johns Hopkins surgeon, Dr. Marty Makary weighed in on a theory that Lyme disease may have originated from a bioweapons laboratory. 6:40pm- In her latest editorial for The New York Post, Miranda Devine writes that a “damning report” labels the Federal Bureau of Investigation (FBI) as a “rudderless ship” and “all f*cked up” under the leadership of Director Kash Patel and Deputy Director Dan Bongino. The report alleges that Bongino has an “unfortunate obsession with social media.”

The Rich Zeoli Show- Full Episode (12/01/2025): 3:05pm- The man allegedly responsible for shooting two National Guard members had been granted asylum from Afghanistan. While on Meet the Press, Department of Homeland Security Secretary Krisit Noem said initial investigations suggest the man became radicalized while in the United States. 3:10pm- In her latest editorial for The New York Post, Miranda Devine writes that a “damning report” labels the Federal Bureau of Investigation (FBI) as a “rudderless ship” and “all f*cked up” under the leadership of Director Kash Patel and Deputy Director Dan Bongino. The report alleges that Bongino has an “unfortunate obsession with social media.” 3:30pm- A report from Ernesto Londono of The New York Times documents rampant fraud plaguing Minnesota—dozens of people have been charged with stealing more than $1 billion in taxpayer money from programs meant to feed hungry children and provide therapy for autistic children. Critics of Governor Tim Walz say his administration allowed the fraud to persist “partly because state officials were fearful of alienating the Somali community” who were largely responsible for the scams. 3:50pm- It's finally here! “Be Nice to Matt DeSantis Week” kicks off. Earlier this year, Linda Kerns—Attorney & Pennsylvania Election Integrity Counsel for the Republican National Committee and Donald Trump—donated money to the Travis Manion Foundation during 1210 WPHT's fundraiser in exchange for Rich guaranteeing he would be nice to Matt for one full week before the end of the year. 4:05pm- A report from Ernesto Londono of The New York Times documents rampant fraud plaguing Minnesota—dozens of people have been charged with stealing more than $1 billion in taxpayer money from programs meant to feed hungry children and provide therapy for autistic children. Critics of Governor Tim Walz say his administration allowed the fraud to persist “partly because state officials were fearful of alienating the Somali community” who were largely responsible for the scams. 4:15pm- Is even Europe getting sick of far-left taxation policies? On Sunday, Switzerland rejected a referendum that would have placed a 50% inheritance tax on assets above 50 million Swiss francs, or about $62 million. 4:40pm- TV recommendations: Death by Lightning on Netflix—which is based on Candece Millard's book on the assassination of President James Garfield. 5:05pm- The man allegedly responsible for shooting two National Guard members had been granted asylum from Afghanistan. While on Meet the Press, Department of Homeland Security Secretary Krisit Noem said initial investigations suggest the man became radicalized while in the United States. National Guard member Sarah Beckstorm, sadly, died from her wounds. Meanwhile, Guardsman Andrew Wolfe remains in critical condition. West Virginia Gov. Patrick Morrisey said Wolfe was responsive on Monday. 5:25pm- Last month, while speaking from the House floor, Rep. Jasmine Crockett (D-TX) accused several Republicans including EPA Administrator Lee Zeldin of taking campaign donations from Jeffrey Epstein. However, her claim was horribly misleading. The donations were from a Dr. Jeffrey Epstein—a different Jeffery Epstein, with no relation to the predator. Astoundingly, Crockett recently doubled down on her outlandish claims during a segment on MS Now. 5:40pm- Linda Kerns calls in to outline the rules for “Be Nice to Matt Week”—so far, Rich has violated every instruction. 6:00pm- A Washington Post report states that Department of War Secretary Pete Hegseth authorized a series of deadly strikes on a drug trafficking boat in the Caribbean, ordering military officials to “kill everybody.” The directive, according to the report, led to a second strike killing several crew members that survived the initial assault on the vessel. 6:20pm- Food and Drug Administration (FDA) Commissioner, and Johns Hopkins surgeon, Dr. Marty Makary weighed in on a theory that ...

Content Warning: This episode discusses eating disorders, starvation, and medical neglect. Listener discretion is advised. This week on Pathology with Dr. Priya, a Zone 7 series, Sheryl McCollum and Dr. Priya Banerjee look at some of the most painful and complex ways a body can fail, from starvation and radiation exposure to delayed deaths that can take years to claim a life. Dr. Priya Breaks down the science of how the body deteriorates during starvation, explains why children in famine zones appear bloated, and discusses both abuse and eating disorder cases that show the psychological and biological devastation of prolonged deprivation. They also explore radiation-linked illnesses, the hidden risks of environmental exposure, and what happens when a wound or poisoning leads to death years later. Through every case, Dr. Priya explains the forensic details behind a “slow death” and why, for the body, nothing about it is slow. Highlights • (0:00) Sheryl welcome listeners and introduces the topic: slow deaths • (3:00) Why Thanksgiving reminds Sheryl of slow deaths and what starvation really is • (4:00) Dr. Priya explains how starvation breaks the body down from within, and how it can stem from both illness and abuse • (12:45) Dr. Priya describes why starving children often appear bloated and the biology behind kwashiorkor• (16:15) Radiation exposure: how time, dose, and distance determine long-term damage • (20:45) Delayed deaths, paralysis, and the challenge of proving causation • (26:15) "Death by a thousand cuts": how blood loss from minor wounds can still be lethal, and how even old wounds can become deadly decades later • (29:00) Closing thoughts: Sheryl and Dr. Priya reflect on the cruelty of slow deaths About the Hosts Dr. Priya Banerjee is a board-certified forensic pathologist with extensive experience in death investigation, clinical forensics, and courtroom testimony. A graduate of Johns Hopkins, she served for over a decade as Rhode Island’s state medical examiner and now runs a private forensic pathology practice. Her work includes military deaths, and high-profile investigations. Dr. Priya has also been featured as a forensic expert on platforms such as CrimeOnline and Crime Stories with Nancy Grace. She is a dedicated educator, animal lover, and proud mom. Website: anchorforensicpathology.com Twitter/X: @Autopsy_MD Sheryl “Mac” McCollum is an active crime scene investigator for a Metro Atlanta Police Department and the director of the Cold Case Investigative Research Institute, which partners with colleges and universities nationwide. With more than 4 decades of experience, she has worked on thousands of cold cases using her investigative system, The Last 24/361, which integrates evidence, media, and advanced forensic testing. Her work on high-profile cases, including The Boston Strangler, Natalie Holloway, Tupac Shakur and the Moore’s Ford Bridge lynching, led to her Emmy Award for CSI: Atlanta and induction into the National Law Enforcement Hall of Fame in 2023. Email: coldcase2004@gmail.com Twitter/X: @ColdCaseTips Facebook: @sheryl.mccollum Instagram: @officialzone7podcast Preorder Sheryl’s upcoming book, Swans Don’t Swim in a Sewer: Lessons in Life, Justice, and Joy from a Forensic Scientist, releasing May 2026 from Simon and Schuster. https://www.simonandschuster.com/books/Swans-Dont-Swim-in-a-Sewer/Sheryl-Mac-McCollum/9798895652824 If this episode gave you a new understanding of the science behind slow deaths, share it with a friend and leave a review. Your support helps others discover the science, the stories, and the heart behind Pathology with Dr. Priya | A Zone 7 Series.See omnystudio.com/listener for privacy information.

Send us a textMost people think memory loss is a downhill slide you can't stop. We don't. In this conversation with neurologist and neuroscientist Dr. Majid Fotuhi, we map out a twelve‑week blueprint that measurably improves memory, focus, and even grows hippocampal volume by targeting the real drivers of decline: poor sleep, chronic stress, insulin resistance, hearing loss, inactivity, and hidden medical issues.Dr. Majid Fotuhi is a pioneering neurologist, neuroscientist, and professor with more than thirty-five years of experience in brain health, memory, neuroplasticity, and the prevention of Alzheimer's disease. His work bridges research, clinical innovation, and public education.He earned his PhD in neuroscience from Johns Hopkins University, completed medical training at Harvard Medical School, and returned to Johns Hopkins for his neurology residency. He currently serves as an adjunct professor at Johns Hopkins University.An author and communicator, Dr. Fotuhi has written several books and is known for making complex science accessible. His excellence in teaching earned him the American Academy of Neurology's prestigious award. His research has appeared in peer-reviewed journals, been presented at major conferences, and cited widely by scientists worldwide.Dr. Fotuhi has created a twelve-week program that has helped thousands of patients with memory loss, brain fog, concussion, mild cognitive impairment, and early Alzheimer's disease. His expertise has been featured by CNN, NBC News, the Today Show, ABC News, The New York Times, The Washington Post, and The Times (London).We start by clarifying what mild cognitive impairment is, how it differs from dementia, and why so many cases are preventable. Dr. Fotuhi explains the “type 3 diabetes” model—how decades of sugar spikes and inflammation erode the blood‑brain barrier and starve neurons of a stable environment. Then we get practical. You'll hear how a personalized “brain portfolio” guides treatment: VO2 max testing to shape exercise, sleep studies and CPAP when needed, targeted brain training that matches deficits, and labs for vitamin D, B12, and omega‑3 status. The results? Early wins in two to three weeks, statistically significant gains at six and twelve, and habits that stick.We don't stop at diet and steps. Oral health impacts cognition by limiting whole foods and increasing inflammation; chewing itself engages neural circuits. Hearing loss quietly accelerates decline—hearing aids can move people from mild impairment back to normal. Add a simple, sustainable food approach—ditch ultra‑processed foods, eat vegetables, legumes, fruits, quality proteins, and healthy fats—and consider targeted supplementation with DHA/EPA omega‑3s and corrected D and B12 levels. Along the way, we address why amyloid hogged the spotlight, and point to powerful data: the Lancet's estimate that 45% of dementia cases are preventable and the American Heart Association's claim that 80% of strokes can be avoided.If you want a sharper brain by summer, this is your starting line. Subscribe, share this with someone you love, and leave a review telling us the one habit you'll change this week. Your future brain will thank you.Links:Majid Fotuhi, MD, PhD: https://drfotuhi.com/https://krieger.jhu.edu/mbi/directory/majid-fotuhi/https://neurogrow.com/about-us/dr-majid-fotuhi-md-phd/https://psychology.columbian.gwu.edu/majid-fotuhiTweet me @realdrhamrahIG @drhamrah

In his weekly clinical update, Dr. Griffin and Vincent Racaniello wish everyone a Happy Thanksgiving and then decry appointment of the Louisiana State surgeon general as deputy chief of the CDC, the 3 children's deaths during this fall's pertussis outbreak, the Marburg virus outbreak in Ethiopia, results of the phase 1 safety trial for the novel poliovirus vaccines nOPV1 and nOPV3, and the first human death from H5N5 influenza virus infection in the US this fall, before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, effectiveness of the cell or egg based flu or the mRNA vaccines, immunogenicity and efficacy of updated COVID-19 vaccines, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, immune and cognitive dysfunction during long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Anti-science Movement: Deputy director of CDC (X:Louisiana Office of the Surgeon General) CDC's new deputy director is vocal critic of vaccines, advocated for ivermectin (CIDRAP) Whooping cough cases on the rise in Texas (FOX4: KDFW) Third infant in Kentucky dies of whooping cough as national cases stay high for second year in a row (CIDRAP) More than 25,000 whooping cough cases reported this year as Kentucky records 3rd infant death (ABC News) Vaccination Coverage and Exemptions among Kindergartners (CDC: SchoolVaxView) Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV‐related disease and harms from vaccination (Cochrane Library) Marburg Outbreak in Ethiopia: Current Situation (CDC: Marburg Virus Disease) Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial (LANCET: Infectious Diseases) Washington state resident believed to be the first to die from a rare strain of bird flu (AP News) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Superior Effectiveness and Estimated Public Health Impact of Cell- Versus Egg-Based Influenza Vaccines in Children and Adults During the US 2023–2024 Season (Infectious Diseases and Therapy) Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine(NEJM) ACIP Recommendations Summary (CDC: Influenza) Types of Influenza Viruses (CDC: Influenza (flu)) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease (CID) FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy: FDA Safety Communication (FDA) Brag Sets Off a Chain Reaction — Dr. Oz Takes the Bait, But Fumbles the Math, and Starts Unraveling Mid-Interview (Atlanta BlackStar) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study (LANCET: Infectious Diseases) Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants (OFID) SARS-CoV-2 vaccination and myositis in Norway and Sweden (Rheumatology) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Digitally Assessed Long COVID Symptomatology Is Associated With Lymphocyte Mitochondrial Dysfunction and Altered Immune Potential (OFID) Evaluation of Interventions for Cognitive Symptoms in Long COVID (JAMA Neurology) Reaching out to US house representative Letters read on TWiV 1274 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

In the wildly popular biohacking and longevity space, Peter Attia is often cited as one of the leading luminaries. His straightforward, science-backed approach seems to cut through the noise in a space dominated by fit bros and wellness grifters who always seem to have a product to sell. But the man who dropped out of residency at Johns Hopkins to found a private clinic focused on longevity has his share of critics, who are a bit suspicious about his self-experimentations—and the millions he makes counseling Silicon Valley insiders about experimental medicine. This week we take a look at longevity broadly and Attia specifically. Derek kicks off the episode with a recap of his time at Eudemonia Summit, where, among other things, he got to debate another leading biohacker, Dave Asprey, about seed oils. As it turns out, longevity was the top buzzword there as well. I Went to Eudemonia – a Wellness Summit with the Industry's Top Thought Leaders – Here's What It Was Like Outlive: A Critical Review  A Review of OUTLIVE Critiquing Peter Attia Andrew Huberman and Peter Attia: Self-enhancement, supplements & doughnuts? Learn more about your ad choices. Visit megaphone.fm/adchoices

Overview This special episode of the Tick Boot Camp Podcast was recorded live at the 2nd Annual Alzheimer's Pathobiome Initiative (AlzPI) and PCOM Symposium in collaboration with Pathobiome Perspectives. Hosted by Ali Moresco in partnership with Nikki Schultek, Executive Director of AlzPI, the conversation brings the Tick Boot Camp mission of exploring infection-associated chronic illness (IACI)—including Lyme disease and other tick-borne infections—to the global Alzheimer's and neuroimmunology research community. Tick Boot Camp co-founders Matt Sabatello and Rich Johannesen partnered with Ali and Nikki to highlight leading scientists connecting infection, immune dysfunction, and cognitive decline. This episode features Dr. Sean Miller, a neuroscientist and co-investigator in the Logan Lab with a primary appointment at Yale School of Medicine, who is developing ways to non-invasively detect Alzheimer's-like pathology through the eye. Guest Sean Miller, PhD Co-Investigator, Logan Lab / Yale School of Medicine Dr. Sean Miller completed pre-doctoral work at Harvard Medical School, earned his PhD from Johns Hopkins University, and completed post-doctoral training at Stanford University. His research focuses on neurodegeneration, neuroglia, and early diagnostic strategies for Alzheimer's and related diseases. At the AlzPI & PCOM Symposium, Dr. Miller presented evidence showing that SARS-CoV-2 (COVID-19) infection can accelerate Alzheimer's-like pathology and that these changes can be detected non-invasively through retinal imaging. His findings suggest that amyloid-beta, a protein long associated with Alzheimer's disease, may also serve as part of the brain's antimicrobial defense system—trapping pathogens like a mesh or biofilm, but leading to damaging plaque buildup when overproduced. Key Discussion Points Dr. Miller describes how the COVID-19 virus can act as an infectious trigger for neuroinflammation and amyloid buildup, how the eye provides a unique window into the brain, and why early detection is essential to preventing neuron death. He shares how his lab's AI-enhanced retinal imaging research at Yale Eye Center is identifying amyloid and tau deposits in patients with long COVID-related brain fog—opening the possibility of routine eye exams doubling as early Alzheimer's screening tools. He explains potential therapeutic strategies, such as limiting amyloid production during infection flare-ups and enhancing clearance mechanisms afterward to reduce chronic plaque formation. The conversation also explores his scientific journey—from designing Alzheimer's drugs at Harvard and Johns Hopkins to realizing the need for early disease detection during his postdoc at Stanford—and how the pandemic inspired his focus on infection-induced neurodegeneration. “We believe neurons are exposed to pathogens in the central nervous system and respond by secreting amyloid-beta to trap them. Excessive plaque buildup from repeated or severe infections may be what drives long-term neurodegeneration.” — Dr. Sean Miller Why It Matters Dr. Miller's research connects infectious disease, ophthalmology, and neurology, providing a revolutionary new method to screen for early Alzheimer's-like changes non-invasively through the human eye. His work suggests that infections like COVID-19 may trigger the same protective—but damaging—immune responses implicated in chronic conditions such as Alzheimer's disease and infection-associated cognitive decline. About the Event The interview took place at the 2nd Annual Alzheimer's Pathobiome Initiative (AlzPI) and Philadelphia College of Osteopathic Medicine (PCOM) Symposium, held on October 3, 2025, at Ohio University in Dublin, Ohio. The event brought together more than 20 global researchers exploring how microbes, the microbiome, and the immune response contribute to Alzheimer's, dementia, PANS/PANDAS, and infection-associated chronic illnesses (IACI). Tick Boot Camp partnered with Ali Moresco and Nikki Schultek to share the voices of researchers advancing the field of infection-associated chronic illness. This episode is part of a multi-part Tick Boot Camp series highlighting how pathobiome and microbiome science are transforming the understanding of Lyme disease, infection, and neurodegeneration. Learn More Learn more about the Alzheimer's Pathobiome Initiative (AlzPI) Listen to Tick Boot Camp Podcast episodes, including Episode 406: Pathobiome – An Interview with Nikki Schultek and Episode 101: The Young Gun – An Interview with Alex (Ali) Moresco discussed in this interview.

A photograph can provide documentation but can’t tell the whole story. This week on Pathology with Dr. Priya, a Zone 7 series, Dr. Priya Banerjee joins Sheryl McCollum to share why revisiting a cold-case scene, sometimes decades later, can completely shift an investigation. When she traveled for hours to inspect an identical car tied to a cold case, she discovered details impossible to see on paper. They talk about how vehicles can become part of the forensic story, why the setting itself matters, and how today’s technology can clarify what investigators once assumed. From seat position to power locks, their conversation highlights what’s lost when professionals rely only on reports and what’s gained when they return to the scene. Highlights • (0:00) Sheryl welcome listeners and introduces the topic: why visiting a scene is essential in cold-case investigations • (1:00) Dr. Priya describers visiting a cold-case scene and inspecting an identical car for accuracy • (2:15) The car as a crime scene: how transport vehicles create multiple evidence locations • (3:30) How changing car technology, from manual locks to sensors, alters forensic interpretation • (5:00) What revisitng a scene reveals that photos and reports cannot • (10:00) Revisiting old neighborhoods and the effects of time, urban change, and memory on case context • (12:00) Dr. Priya’s methodical process for documenting and photographing scene and how that strengthens her courtroom testimony • (13:15) Returning submerged and long-missing vehicles and bringing families long-awaited closure • (14:30) Dr. Priya on method, teamwork, and why working cold cases feels like giving back • (20:45) Revisiting old files with fresh eyes: how old photos, modern technology, and tools like Othram and NamUs can finally move cold cases forward About the Hosts Dr. Priya Banerjee is a board-certified forensic pathologist with extensive experience in death investigation, clinical forensics, and courtroom testimony. A graduate of Johns Hopkins, she served for over a decade as Rhode Island’s state medical examiner and now runs a private forensic pathology practice. Her work includes military deaths, and high-profile investigations. Dr. Priya has also been featured as a forensic expert on platforms such as CrimeOnline and Crime Stories with Nancy Grace. She is a dedicated educator, animal lover, and proud mom. Website: anchorforensicpathology.com Twitter/X: @Autopsy_MD Sheryl McCollum is an Emmy Award–winning CSI, a writer for CrimeOnline, and the Forensic and Crime Scene Expert for Crime Stories with Nancy Grace. She works as a CSI for a metro Atlanta Police Department and is the co- author of the textbook Cold Case: Pathways to Justice. Sheryl is also the founder and director of the Cold Case Investigative Research Institute (CCIRI), a nationally recognized nonprofit that brings together universities, law enforcement, and experts to help solve unsolved homicides, missing persons cases, and kidnappings. Email: coldcase2004@gmail.com Twitter/X: @ColdCaseTips Facebook: @sheryl.mccollum Instagram: @officialzone7podcast If this episode gave you a new understanding of cold case investigations, share it with a friend and leave a review. Your support helps others discover the science, the stories, and the heart behind Pathology with Dr. Priya | A Zone 7 Series. See omnystudio.com/listener for privacy information.

As millions of Americans hit the road to visit family for Thanksgiving, many will pass through, or return to, rural communities. Nearly 60 million Americans live in these areas, yet many struggle to access even basic healthcare as rural hospitals close at record rates.Dr. Jennifer Schneider, co-founder and CEO of Homeward Health, is tackling this crisis head-on by reimagining how care is delivered to Medicare Advantage members in rural America. Drawing on her experiences as a physician, a patient with Type 1 diabetes, and the former president of Livongo, Jenny shares why rural healthcare is both a massive challenge and an untapped opportunity.We cover:

Health care strategist Dana Y. Lujan discusses her article "Why direct primary care (DPC) models fail." Dana argues that the DPC community's obsession with "purity" is missing the point, stating that these models don't fail over ideology, they fail because of bad math. She uses the University of Houston's $1 million clinic failure as a prime example of a "fundamental market mismatch," where a DPC model was placed in a low-income area that couldn't sustain its membership fees (a ~70 percent revenue deficit). Dana also debunks the myth that institutions can't run successful DPC programs, citing CHI Health and Johns Hopkins as proof that financial sustainability and market fit are the true keys. This episode explores the critical difference between what's legally permissible and what's operationally sustainable, and why the DPC conversation must shift from philosophy to execution. Learn why you cannot "subscription-model your way out of poverty." Our presenting sponsor is Microsoft Dragon Copilot. Want to streamline your clinical documentation and take advantage of customizations that put you in control? What about the ability to surface information right at the point of care or automate tasks with just a click? Now, you can. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Offering an extensible AI workspace and a single, integrated platform, Dragon Copilot can help you unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's part of Microsoft Cloud for Healthcare, built on a foundation of trust. Ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

In light of the overturned ruling of Kowalski v Johns Hopkins and Serial's The Preventionist, we're reairing an episode from our Kowalski season in which Andrea dives into the complexities around reporting child abuse suspicions. *** With the jury's stunning $242 million verdict in favor of the Kowalski family, host Andrea Dunlop looks at why this case has struck such a nerve on both sides of the political spectrum. She examines why some mothers accused of medical child abuse are viewed as monsters and others as martyrs.   Andrea looks at the charges against social worker Cathy Bedy the woman who became the face of the child welfare bureaucracy during the Maya Kowalski case and examines her testimony.   We also seek out answers about the troubled state of child welfare in America by talking to Dr. Jessica Pryce, author of the forthcoming book Broken: Transforming Child Protective Services—Notes of a Former Caseworker.  Dr. Pryce shares heart-wrenching stories of mothers whose lives have been turned upside down by investigations and sets out a compelling and urgent case for an overhaul of CPS. With her inside view of the system, she also gives insight on how doctors and other mandated reporters can do the best for the families they want to help even within the current, deeply flawed system.   This episode grapples with the complexity around reporting child abuse suspicions and the potentially chilling ripple effects of the explosive verdict in Kowalski v Johns Hopkins All Childrens. It examines the lack of support for struggling parents in America, while leaving the listener with urgent questions about justice and equity.  *** Learn more about Dr. Pryce's work on her website: https://jessicaprycephd.com/   Tickets for Nobody Should Believe Me LIVE: https://www.andreadunlop.net/nobody-should-believe-me-live Order Andrea's book The Mother Next Door: Medicine, Deception, and Munchausen by Proxy.  Click here to view our sponsors. Remember that using our codes helps advertisers know you're listening and helps us keep making the show!   Subscribe on YouTube where we have full episodes and lots of bonus content.  Follow Andrea on Instagram: @andreadunlop Buy Andrea's books here.  For more information and resources on Munchausen by Proxy, please visit MunchausenSupport.com The American Professional Society on the Abuse of Children's MBP Practice Guidelines can be downloaded here.  Learn more about your ad choices. Visit podcastchoices.com/adchoices